Yoshiya Tanaka

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2781484/publications.pdf

Version: 2024-02-01

685	30,312	7568 77	8396 147
papers	citations	h-index	g-index

777	777	777	22907
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Modern Rheumatology, 2012, 22, 21-30.	1.8	1,294
2	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2019, 71, 1400-1412.	5.6	1,098
3	Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Modern Rheumatology, 2012, 22, 21-30.	1.8	947
4	T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-lÎ². Nature, 1993, 361, 79-82.	27.8	869
5	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2019, 78, 1151-1159.	0.9	759
6	Trial of Anifrolumab in Active Systemic Lupus Erythematosus. New England Journal of Medicine, 2020, 382, 211-221.	27.0	725
7	Lymphocyte interactions with endothelial cells. Trends in Immunology, 1992, 13, 106-112.	7.5	669
8	A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details. Modern Rheumatology, 2012, 22, 1-14.	1.8	662
9	Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. New England Journal of Medicine, 2017, 376, 652-662.	27.0	643
10	Tofacitinib (CPâ€690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelveâ€month data from a twentyâ€fourâ€“month phase III randomized radiographic study. Arthritis and Rheumatism, 2013, 65, 559-570.	6.7	481
11	A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details. Modern Rheumatology, 2012, 22, 1-14.	1.8	453
12	Proteoglycans on endothelial cells present adhesion-inducing cytokines to leukocytes. Trends in Immunology, 1993, 14, 111-115.	7.5	412
13	Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet, The, 2018, 392, 222-231.	13.7	396
14	Janus kinase inhibitors in autoimmune diseases. Annals of the Rheumatic Diseases, 2013, 72, ii111-ii115.	0.9	350
15	Osteoblasts and Osteoclasts in Bone Remodeling and Inflammation. Inflammation and Allergy: Drug Targets, 2005, 4, 325-328.	3.1	321
16	Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5â€…years: integrated analysis of data from the global clinical trials. Annals of the Rheumatic Diseases, 2017, 76, 1253-1262.	0.9	316
17	The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4â€Related Disease. Arthritis and Rheumatology, 2020, 72, 7-19.	5.6	292
18	Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Annals of the Rheumatic Diseases, 2006, 66, 470-475.	0.9	282

#	Article	IF	Citations
19	Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Annals of the Rheumatic Diseases, 2018, 77, 348-354.	0.9	279
20	Phase II study of tofacitinib (CPâ€690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care and Research, 2011, 63, 1150-1158.	3.4	259
21	Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Annals of the Rheumatic Diseases, 2010, 69, 1286-1291.	0.9	251
22	Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet, The, 2019, 393, 2303-2311.	13.7	237
23	Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions. Annals of the Rheumatic Diseases, 2016, 75, 1428-1437.	0.9	232
24	Relationship between fluctuations in glucose levels measured by continuous glucose monitoring and vascular endothelial dysfunction in type 2 diabetes mellitus. Cardiovascular Diabetology, 2013, 12, 1.	6.8	215
25	The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferonâ€Î³3 and interleukinâ€17 production by human CD4+ T cells. Arthritis and Rheumatism, 2012, 64, 1790-1798.	6.7	196
26	A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Annals of the Rheumatic Diseases, 2018, 77, 355-363.	0.9	196
27	Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nature Reviews Rheumatology, 2022, 18, 133-145.	8.0	193
28	JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial. Nephrology Dialysis Transplantation, 2018, 33, 1950-1959.	0.7	183
29	Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy. Arthritis and Rheumatology, 2017, 69, 1960-1968.	5.6	182
30	Effectiveness and Safety of Tocilizumab: Postmarketing Surveillance of 7901 Patients with Rheumatoid Arthritis in Japan. Journal of Rheumatology, 2014, 41, 15-23.	2.0	174
31	Postmarketing Surveillance of the Safety and Effectiveness of Etanercept in Japan. Journal of Rheumatology, 2009, 36, 898-906.	2.0	167
32	Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients. Annals of the Rheumatic Diseases, 2011, 70, 2148-2151.	0.9	166
33	The changing landscape of biosimilars in rheumatology. Annals of the Rheumatic Diseases, 2016, 75, 974-982.	0.9	160
34	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Annals of the Rheumatic Diseases, 2021, 80, 71-87.	0.9	158
35	Effect of denosumab on Japanese patients with rheumatoid arthritis: a doseâ€ response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)â€"a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial. Annals of the Rheumatic Diseases, 2016, 75, 983-990.	0.9	157
36	Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study. Annals of the Rheumatic Diseases, 2015, 74, 389-395.	0.9	149

#	Article	IF	Citations
37	Incidence and Risk Factors for Serious Infection in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors: A Report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety. Journal of Rheumatology, 2011, 38, 1258-1264.	2.0	141
38	Clinical Trials Express:Fracture Risk Reduction With Denosumab in Japanese Postmenopausal Women and Men With Osteoporosis: Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT). Journal of Clinical Endocrinology and Metabolism, 2014, 99, 2599-2607.	3.6	138
39	The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells. Annals of the Rheumatic Diseases, 2014, 73, 2192-2198.	0.9	136
40	Chondrocytes Are Regulated by Cellular Adhesion Through CD44 and Hyaluronic Acid Pathway. Journal of Bone and Mineral Research, 1997, 12, 1657-1663.	2.8	132
41	Interleukinâ€1Î² induces differentiation of human mesenchymal stem cells into osteoblasts via the Wntâ€5a/receptor tyrosine kinaseâ€“like orphan receptor 2 pathway. Arthritis and Rheumatism, 2012, 64, 3355-3363.	6.7	132
42	Antagonizing dopamine D1-like receptor inhibits Th17 cell differentiation: Preventive and therapeutic effects on experimental autoimmune encephalomyelitis. Biochemical and Biophysical Research Communications, 2008, 373, 286-291.	2.1	131
43	Tocilizumab in patients with adult-onset stillâ€™s disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial. Annals of the Rheumatic Diseases, 2018, 77, 1720-1729.	0.9	129
44	Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Annals of the Rheumatic Diseases, 2021, 80, 304-311.	0.9	129
45	Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study. Annals of the Rheumatic Diseases, 2016, 75, 1057-1064.	0.9	125
46	Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. Annals of the Rheumatic Diseases, 2021, 80, 848-858.	0.9	123
47	Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study. Arthritis Research and Therapy, 2016, 18, 34.	3.5	117
48	Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study. Journal of Rheumatology, 2016, 43, 504-511.	2.0	110
49	Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study. Modern Rheumatology, 2015, 25, 514-521.	1.8	109
50	A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Modern Rheumatology, 2007, 17, 191-197.	1.8	107
51	Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE) Tj ETQq1 1 0.784314 rgBT /Overlock 1 2019, 78, 899-907.	0.9	105
52	Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study. Annals of the Rheumatic Diseases, 2012, 71, 817-824.	0.9	102
53	Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Annals of the Rheumatic Diseases, 2013, 72, 482-492.	0.9	102
54	Advanced glycation end products increase endothelial permeability through the RAGE/Rho signaling pathway. FEBS Letters, 2010, 584, 61-66.	2.8	100

#	Article	IF	Citations
55	Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: Postmarketing surveillance report of 7740 patients. Modern Rheumatology, 2014, 24, 390-398.	1.8	100
56	Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. RMD Open, 2020, 6, e001395.	3.8	100
57	Osteoblasts are regulated by the cellular adhesion through ICAM-1 and VCAM-1. Journal of Bone and Mineral Research, 1995, 10, 1462-1469.	2.8	97
58	Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. Modern Rheumatology, 2011, 21, 343-351.	1.8	95
59	Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan. Annals of the Rheumatic Diseases, 2019, 78, 1305-1319.	0.9	95
60	The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression. Annals of the Rheumatic Diseases, 2016, 75, 75-83.	0.9	94
61	Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study. Lancet, The, 2017, 389, 1206-1217.	13.7	94
62	Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis. Rheumatology, 2019, 58, 336-344.	1.9	92
63	A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Modern Rheumatology, 2007, 17, 191-197.	1.8	92
64	Discontinuation of biologics in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology, 2013, 31, S22-7.	0.8	91
65	Janus Kinase Inhibitor Baricitinib Modulates Human Innate and Adaptive Immune System. Frontiers in Immunology, 2018, 9, 1510.	4.8	89
66	Fractalkine, a CX 3 Câ€chemokine, functions predominantly as an adhesion molecule in monocytic cell line THPâ€1. Immunology and Cell Biology, 2001, 79, 298-302.	2.3	86
67	Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3). Annals of the Rheumatic Diseases, 2019, 78, 1320-1332.	0.9	85
68	Stateâ€ofâ€theâ€art treatment of systemic lupus erythematosus. International Journal of Rheumatic Diseases, 2020, 23, 465-471.	1.9	85
69	IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab. Annals of the Rheumatic Diseases, 2014, 73, 1595-1597.	0.9	84
70	Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus. Journal of Diabetes Investigation, 2014, 5, 313-319.	2.4	84
71	Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study. Annals of the Rheumatic Diseases, 2017, 76, 1853-1861.	0.9	83
72	Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study. Annals of the Rheumatic Diseases, 2014, 73, 536-543.	0.9	82

#	Article	IF	Citations
73	Contribution of the Interleukinâ€6/STATâ€3 Signaling Pathway to Chondrogenic Differentiation of Human Mesenchymal Stem Cells. Arthritis and Rheumatology, 2015, 67, 1250-1260.	5.6	82
74	Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients. Modern Rheumatology, 2012, 22, 498-508.	1.8	81
75	Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). Annals of the Rheumatic Diseases, 2016, 75, 1917-1923.	0.9	81
76	Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study. Rheumatology, 2020, 59, 2427-2434.	1.9	81
77	Intercellular Adhesion Molecule 1 Discriminates Functionally Different Populations of Human Osteoblasts: Characteristic Involvement of Cell Cycle Regulators. Journal of Bone and Mineral Research, 2000, 15, 1912-1923.	2.8	80
78	Clinical relevance of the expression of P-glycoprotein on peripheral blood lymphocytes to steroid resistance in patients with systemic lupus erythematosus. Arthritis and Rheumatism, 2005, 52, 1676-1683.	6.7	80
79	Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis. Modern Rheumatology, 2016, 26, 491-498.	1.8	80
80	A multi-biomarker score measures rheumatoid arthritis disease activity in the BeSt study. Rheumatology, 2013, 52, 1202-1207.	1.9	79
81	Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients--REACTION 52-week study. Rheumatology, 2011, 50, 1908-1915.	1.9	78
82	Constitutive Chemokine Production Results in Activation of Leukocyte Function-Associated Antigen-1 on Adult T-Cell Leukemia Cells. Blood, 1998, 91, 3909-3919.	1.4	75
83	Continuation of Methotrexate Resulted in Better Clinical and Radiographic Outcomes Than Discontinuation upon Starting Etanercept in Patients with Rheumatoid Arthritis: 52-week Results from the JESMR Study. Journal of Rheumatology, 2011, 38, 1585-1592.	2.0	75
84	Peripheral Immunophenotyping Identifies Three Subgroups Based on T Cell Heterogeneity in Lupus Patients. Arthritis and Rheumatology, 2017, 69, 2029-2037.	5.6	74
85	Human mesenchymal stem cells inhibit osteoclastogenesis through osteoprotegerin production. Arthritis and Rheumatism, 2011, 63, 1658-1667.	6.7	73
86	Metabolic Reprogramming Commits Differentiation of Human CD27+IgD+ B Cells to Plasmablasts or CD27â^'IgDâ^' Cells. Journal of Immunology, 2017, 199, 425-434.	0.8	72
87	Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial. Modern Rheumatology, 2012, 22, 382-393.	1.8	71
88	Differential effects of biological DMARDs on peripheral immune cell phenotypes in patients with rheumatoid arthritis. Rheumatology, 2018, 57, 164-174.	1.9	70
89	Efficacy of combination therapy of anti-TNF-Î± antibody infliximab and methotrexate in refractory entero-BehÃ§etâ€™s disease. Modern Rheumatology, 2011, 21, 184-191.	1.8	69
90	Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis. Modern Rheumatology, 2015, 25, 817-824.	1.8	69

#	Article	IF	Citations
91	Î²1 Integrin/Focal Adhesion Kinase-mediated Signaling Induces Intercellular Adhesion Molecule 1 and Receptor Activator of Nuclear Factor Î°B Ligand on Osteoblasts and Osteoclast Maturation. Journal of Biological Chemistry, 2003, 278, 45368-45374.	3.4	68
92	CD44 Is the Physiological Trigger of Fas Up-Regulation on Rheumatoid Synovial Cells. Journal of Immunology, 2001, 167, 1198-1203.	0.8	67
93	Current concepts in the management of rheumatoid arthritis. Korean Journal of Internal Medicine, 2016, 31, 210-218.	1.7	67
94	Up-Regulation of TLR7-Mediated IFN-Î± Production by Plasmacytoid Dendritic Cells in Patients With Systemic Lupus Erythematosus. Frontiers in Immunology, 2018, 9, 1957.	4.8	66
95	Hydroxychloroquine efficiently suppresses inflammatory responses of human class-switched memory B cells via Toll-like receptor 9 inhibition. Clinical Immunology, 2018, 195, 1-7.	3.2	66
96	Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study). Modern Rheumatology, 2011, 21, 122-133.	1.8	65
97	IL-6 and sIL-6R induces STAT3-dependent differentiation of human VSMCs into osteoblast-like cells through JMJD2B-mediated histone demethylation of RUNX2. Bone, 2019, 124, 53-61.	2.9	65
98	Increased expression levels of monocyte CCR2 and monocyte chemoattractant protein-1 in patients with diabetes mellitus. Biochemical and Biophysical Research Communications, 2006, 344, 780-785.	2.1	64
99	Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twentyâ€Fourâ€“Month, Phase <scp>III</scp> Study. Arthritis and Rheumatology, 2019, 71, 878-891.	5.6	64
100	Hypoxia-inducible factor-1Î± induces cell cycle arrest of endothelial cells. Genes To Cells, 2002, 7, 143-149.	1.2	63
101	Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside. Journal of Biochemistry, 2015, 158, 173-179.	1.7	63
102	Mechanisms and therapeutic targets for bone damage in rheumatoid arthritis, in particular the RANK-RANKL system. Current Opinion in Pharmacology, 2018, 40, 110-119.	3.5	63
103	RANKL: A therapeutic target for bone destruction in rheumatoid arthritis. Modern Rheumatology, 2018, 28, 9-16.	1.8	63
104	A multicenter phase II prospective clinical trial of glucocorticoid for patients with untreated IgG4-related disease. Modern Rheumatology, 2017, 27, 849-854.	1.8	62
105	Expansion of T follicular helper-T helper 1 like cells through epigenetic regulation by signal transducer and activator of transcription factors. Annals of the Rheumatic Diseases, 2018, 77, 1354-1361.	0.9	62
106	Induction of RANKL expression and osteoclast maturation by the binding of fibroblast growth factor 2 to heparan sulfate proteoglycan on rheumatoid synovial fibroblasts. Arthritis and Rheumatism, 2004, 50, 2450-2458.	6.7	61
107	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2). Modern Rheumatology, 2008, 18, 146-152.	1.8	61
108	Autocrine Induction of the Human Pro-IL-1Î² Gene Promoter by IL-1Î² in Monocytes. Journal of Immunology, 2002, 168, 1984-1991.	0.8	60

#	Article	IF	Citations
109	Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial. Modern Rheumatology, 2010, 20, 531-538.	1.8	60
110	Phenotypic Changes of Lymphocytes in Patients with Systemic Lupus Erythematosus Who Are in Longterm Remission After B Cell Depletion Therapy with Rituximab. Journal of Rheumatology, 2011, 38, 633-641.	2.0	60
111	Activation of Syk in Peripheral Blood B Cells in Patients With Rheumatoid Arthritis: A Potential Target for Abatacept Therapy. Arthritis and Rheumatology, 2015, 67, 63-73.	5.6	59
112	Correlation of T follicular helper cells and plasmablasts with the development of organ involvement in patients with IgG4-related disease. Rheumatology, 2018, 57, 514-524.	1.9	59
113	CD44 stimulation down-regulates Fas expression and Fas-mediated apoptosis of lung cancer cells. International Immunology, 2001, 13, 1309-1319.	4.0	58
114	Prophylaxis for Pneumocystis pneumonia in patients with rheumatoid arthritis treated with biologics, based on risk factors found in a retrospective study. Arthritis Research and Therapy, 2014, 16, R43.	3.5	58
115	Th22 Cells Promote Osteoclast Differentiation via Production of IL-22 in Rheumatoid Arthritis. Frontiers in Immunology, 2018, 9, 2901.	4.8	58
116	Transcriptional regulation of multidrug resistance-1 gene by interleukin-2 in lymphocytes. Genes To Cells, 2004, 9, 1265-1273.	1.2	57
117	H-Ras signals to cytoskeletal machinery in induction of integrin-mediated adhesion of T cells. Journal of Immunology, 1999, 163, 6209-16.	0.8	57
118	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). Modern Rheumatology, 2007, 17, 28-32.	1.8	56
119	Tacrolimus, a Calcineurin Inhibitor, Overcomes Treatment Unresponsiveness Mediated by P-glycoprotein on Lymphocytes in Refractory Rheumatoid Arthritis. Journal of Rheumatology, 2010, 37, 512-520.	2.0	56
120	Low complements and high titre of anti-Sm antibody as predictors of histopathologically proven silent lupus nephritis without abnormal urinalysis in patients with systemic lupus erythematosus. Rheumatology, 2015, 54, 405-412.	1.9	55
121	B-cell subsets, signaling and their roles in secretion of autoantibodies. Lupus, 2016, 25, 850-856.	1.6	54
122	Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab. Modern Rheumatology, 2017, 27, 237-245.	1.8	54
123	Safety, pharmacokinetics, and efficacy of E6011, an antifractalkine monoclonal antibody, in a first-in-patient phase 1/2 study on rheumatoid arthritis. Modern Rheumatology, 2018, 28, 58-65.	1.8	54
124	Factors in glucocorticoid regimens associated with treatment response and relapses of IgG4-related disease: a multicentre study. Scientific Reports, 2018, 8, 10262.	3.3	54
125	JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical. Modern Rheumatology, 2013, 23, 415-424.	1.8	53
126	Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry. Arthritis Research and Therapy, 2015, 17, 74.	3.5	53

#	Article	IF	Citations
127	Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: Results from a randomized phase II trial. Modern Rheumatology, 2016, 26, 15-23.	1.8	53
128	Induction of Regulatory T Cells and Its Regulation with Insulin-like Growth Factor/Insulin-like Growth Factor Binding Protein-4 by Human Mesenchymal Stem Cells. Journal of Immunology, 2017, 199, 1616-1625.	0.8	53
129	IL-6-accelerated calcification by induction of ROR2 in human adipose tissue-derived mesenchymal stem cells is STAT3 dependent. Rheumatology, 2014, 53, 1282-1290.	1.9	52
130	Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis. BioDrugs, 2016, 30, 407-419.	4.6	52
131	Rheumatoid arthritis. Inflammation and Regeneration, 2020, 40, 20.	3.7	52
132	Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials. Modern Rheumatology, 2021, 31, 1-12.	1.8	52
133	Heparan sulfate proteoglycan on endothelium efficiently induces integrin-mediated T cell adhesion by immobilizing chemokines in patients with rheumatoid synovitis. Arthritis and Rheumatism, 1998, 41, 1365-1377.	6.7	51
134	Effects of anti-TNF-Â antibody infliximab in refractory entero-Behcet's disease. Rheumatology, 2009, 48, 1012-1013.	1.9	51
135	Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24â€…weeks. Annals of the Rheumatic Diseases, 2013, 72, 1488-1495.	0.9	51
136	Splicing variant of WDFY4 augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis. Annals of the Rheumatic Diseases, 2018, 77, 602-611.	0.9	51
137	Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. Modern Rheumatology, 2011, 21, 343-351.	1.8	51
138	Alendronate Protects Premenopausal Women from Bone Loss and Fracture Associated with High-dose Glucocorticoid Therapy. Journal of Rheumatology, 2008, 35, 2249-2254.	2.0	50
139	Multicenter double-blind randomized controlled trial to evaluate the effectiveness and safety of bortezomib as a treatment for refractory systemic lupus erythematosus. Modern Rheumatology, 2018, 28, 986-992.	1.8	50
140	Efficacy of combination therapy of anti-TNF-Î± antibody infliximab and methotrexate in refractory entero-BehÃ§etâ€™s disease. Modern Rheumatology, 2011, 21, 184-191.	1.8	50
141	Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study. RMD Open, 2022, 8, e002012.	3.8	50
142	Monocyte chemoattractant protein-1 induces scavenger receptor expression and monocyte differentiation into foam cells. Biochemical and Biophysical Research Communications, 2003, 305, 380-385.	2.1	49
143	Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial. Modern Rheumatology, 2014, 24, 715-724.	1.8	49
144	Why remission is not enough: underlying disease mechanisms in RA that prevent cure. Nature Reviews Rheumatology, 2021, 17, 135-144.	8.0	49

#	Article	IF	Citations
145	2019 Diagnostic criteria for mixed connective tissue disease (MCTD): From the Japan research committee of the ministry of health, labor, and welfare for systemic autoimmune diseases. Modern Rheumatology, 2021, 31, 29-33.	1.8	49
146	Conversion of T Follicular Helper Cells to T Follicular Regulatory Cells by Interleukinâ€2 Through Transcriptional Regulation in Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2021, 73, 132-142.	5.6	48
147	Galectin-9 induces osteoblast differentiation through the CD44/Smad signaling pathway. Biochemical and Biophysical Research Communications, 2010, 394, 317-322.	2.1	47
148	Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules. Annals of the Rheumatic Diseases, 2012, 71, 1820-1826.	0.9	47
149	Timeâ€dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis. Arthritis Care and Research, 2012, 64, 1125-1134.	3.4	47
150	Mast cellâ€“derived tryptase inhibits apoptosis of human rheumatoid synovial fibroblasts via rhoâ€mediated signaling. Arthritis and Rheumatism, 2010, 62, 952-959.	6.7	46
151	Pneumocystis jiroveciipneumonia associated with etanercept treatment in patients with rheumatoid arthritis: a retrospective review of 15 cases and analysis of risk factors. Modern Rheumatology, 2012, 22, 849-858.	1.8	46
152	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). Modern Rheumatology, 2007, 17, 28-32.	1.8	46
153	Spontaneous Differentiation of Human Mesenchymal Stem Cells on Poly-Lactic-Co-Glycolic Acid Nano-Fiber Scaffold. PLoS ONE, 2016, 11, e0153231.	2.5	46
154	Dopamine D2-like receptor signaling suppresses human osteoclastogenesis. Bone, 2013, 56, 1-8.	2.9	45
155	Clinical immunity in bone and joints. Journal of Bone and Mineral Metabolism, 2019, 37, 2-8.	2.7	45
156	Intensive treatment and treatment holiday of TNF-inhibitors in rheumatoid arthritis. Current Opinion in Rheumatology, 2012, 24, 319-326.	4.3	44
157	Next stage of RA treatment: is TNF inhibitor-free remission a possible treatment goal?. Annals of the Rheumatic Diseases, 2013, 72, ii124-ii127.	0.9	44
158	Clinical practice guideline for SjÃ¶grenâ€™s syndrome 2017. Modern Rheumatology, 2018, 28, 383-408.	1.8	44
159	Lymphocytic focus score is positively related to airway and interstitial lung diseases in primary SjÃ¶gren's syndrome. Respiratory Medicine, 2018, 137, 95-102.	2.9	44
160	Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials. Modern Rheumatology, 2020, 30, 36-43.	1.8	44
161	Amplification of Toll-like receptorâ€“mediated signaling through spleen tyrosine kinase in human B-cell activation. Journal of Allergy and Clinical Immunology, 2012, 129, 1594-1601.e2.	2.9	43
162	Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study). Annals of the Rheumatic Diseases, 2018, 77, 1268-1275.	0.9	43

#	Article	IF	Citations
163	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2). Modern Rheumatology, 2008, 18, 146-152.	1.8	43
164	Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial. Modern Rheumatology, 2010, 20, 531-538.	1.8	43
165	Macrophage Inflammatory Protein-1Î± Induces Hypercalcemia in Adult T-Cell Leukemia. Journal of Bone and Mineral Research, 2004, 19, 1105-1111.	2.8	42
166	Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission. Modern Rheumatology, 2008, 18, 460-464.	1.8	42
167	Cell-autonomous role of TGFÎ² and IL-2 receptors in CD4+ and CD8+ inducible regulatory T-cell generation during GVHD. Blood, 2012, 119, 5575-5583.	1.4	42
168	IL-17 Inhibits Chondrogenic Differentiation of Human Mesenchymal Stem Cells. PLoS ONE, 2013, 8, e79463.	2.5	42
169	Effectiveness of abatacept for patients with SjÃ¶grenâ€™s syndrome associated with rheumatoid arthritis. An open label, multicenter, one-year, prospective study: ROSE (Rheumatoid Arthritis with Orencia Trial) Tj ETQq1 1 0.784314 rgBT /Ov	0.8	42
170	BAFF- and APRIL-targeted therapy in systemic autoimmune diseases. Inflammation and Regeneration, 2016, 36, 6.	3.7	42
171	Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching. Annals of the Rheumatic Diseases, 2016, 75, 1321-1327.	0.9	42
172	A Critical Role for Cyclin C in Promotion of the Hematopoietic Cell Cycle by Cooperation with c-Myc. Molecular and Cellular Biology, 1998, 18, 3445-3454.	2.3	41
173	Activated Platelets and Endothelial Cell Interaction with Neutrophils under Flow Conditions.. Internal Medicine, 2001, 40, 1085-1092.	0.7	41
174	Amplification of IL-21 signalling pathway through Brutonâ€™s tyrosine kinase in human B cell activation. Rheumatology, 2015, 54, 1488-1497.	1.9	41
175	Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study. Rheumatology, 2020, 59, 3303-3313.	1.9	41
176	The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries. Rheumatology, 2021, 60, 820-828.	1.9	41
177	Leflunomide Inhibits PDK1/Akt Pathway and Induces Apoptosis of Human Mast Cells. Journal of Immunology, 2007, 179, 6479-6484.	0.8	40
178	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2J). Modern Rheumatology, 2008, 18, 447-454.	1.8	40
179	Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: The HIKARI randomized, placebo-controlled trial. Modern Rheumatology, 2014, 24, 552-560.	1.8	40
180	Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events. Rheumatology, 2014, 53, 914-918.	1.9	40

#	Article	IF	Citations
181	Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy. Modern Rheumatology, 2016, 26, 80-86.	1.8	40
182	Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years. Annals of the Rheumatic Diseases, 2022, 81, 184-192.	0.9	40
183	H-Ras/Mitogen-activated Protein Kinase Pathway Inhibits Integrin-mediated Adhesion and Induces Apoptosis in Osteoblasts. Journal of Biological Chemistry, 2002, 277, 21446-21452.	3.4	39
184	Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational study. Arthritis Research and Therapy, 2013, 15, R135.	3.5	39
185	Efficacy of combination of Ezetimibe 10Âmg and rosuvastatin 2.5Âmg versus rosuvastatin 5Âmg monotherapy for hypercholesterolemia in patients with type 2 diabetes. Lipids in Health and Disease, 2013, 12, 137.	3.0	39
186	Longterm Safety and Efficacy of Subcutaneous Tocilizumab Monotherapy: Results from the 2-year Open-label Extension of the MUSASHI Study. Journal of Rheumatology, 2015, 42, 799-809.	2.0	39
187	Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan. Rheumatology, 2015, 54, 683-691.	1.9	39
188	Relevance of interferon-gamma in pathogenesis of life-threatening rapidly progressive interstitial lung disease in patients with dermatomyositis. Arthritis Research and Therapy, 2018, 20, 240.	3.5	39
189	Distinct phenotype of leukemic T cells with various tissue tropisms. Journal of Immunology, 1997, 158, 3822-9.	0.8	39
190	C5a promotes migration, proliferation, and vessel formation in endothelial cells. Inflammation Research, 2010, 59, 659-666.	4.0	38
191	Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). Modern Rheumatology, 2012, 22, 327-338.	1.8	38
192	Tofacitinib, a JAK inhibitor, inhibits human B cell activation in vitro. Annals of the Rheumatic Diseases, 2014, 73, 2213-2215.	0.9	38
193	Increased Syk phosphorylation leads to overexpression of TRAF6 in peripheral B cells of patients with systemic lupus erythematosus. Lupus, 2015, 24, 695-704.	1.6	38
194	Effects of exenatide on postprandial vascular endothelial dysfunction in type 2 diabetes mellitus. Cardiovascular Diabetology, 2015, 14, 25.	6.8	38
195	Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. Annals of the Rheumatic Diseases, 2022, 81, 951-961.	0.9	38
196	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. Annals of the Rheumatic Diseases, 2021, 80, 775-781.	0.9	37
197	Crosslinking of CD44 on human osteoblastic cells upregulates ICAM-1 and VCAM-1. FEBS Letters, 2003, 539, 45-50.	2.8	36
198	Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial. Annals of the Rheumatic Diseases, 2017, 76, 1348-1356.	0.9	36

#	Article	IF	Citations
199	Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials. Modern Rheumatology, 2018, 28, 583-591.	1.8	36
200	Associated factors of poor treatment outcomes in patients with giant cell arteritis: clinical implication of large vessel lesions. Arthritis Research and Therapy, 2020, 22, 72.	3.5	36
201	Activation of ‹scp›W‹/scp›nt5aâ€‹‹scp›R‹/scp›or2 signaling associated with epithelialâ€‹toâ€‹mesenchymal transition of tubular epithelial cells during renal fibrosis. Genes To Cells, 2013, 18, 608-619.	1.2	35
202	Disease severity and economic burden in Japanese patients with systemic lupus erythematosus: A retrospective, observational study. International Journal of Rheumatic Diseases, 2018, 21, 1609-1618.	1.9	35
203	Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways. Lupus Science and Medicine, 2020, 7, e000424.	2.7	35
204	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. Annals of the Rheumatic Diseases, 2020, 79, 1333-1339.	0.9	35
205	A review of upadacitinib in rheumatoid arthritis. Modern Rheumatology, 2020, 30, 779-787.	1.8	35
206	Efficacy and safety of abatacept for patients with SjÃ¶gren's syndrome associated with rheumatoid arthritis: Rheumatoid Arthritis with Orencia Trial toward SjÃ¶gren's syndrome Endocrinopathy (ROSE) trialâ€”an open-label, one-year, prospective studyâ€”Interim analysis of 32 patients for 24 weeks. Modern Rheumatology, 2015, 25, 187-193.	1.8	34
207	Efficacy and safety of mizoribine for the treatment of SjÃ¶gren's syndrome: a multicenter open-label clinical trial. Modern Rheumatology, 2007, 17, 464-469.	1.8	33
208	Interaction of Galectin-9 With Lipid Rafts Induces Osteoblast Proliferation Through the c-Src/ERK Signaling Pathway. Journal of Bone and Mineral Research, 2008, 23, 278-286.	2.8	33
209	Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis. Expert Review of Clinical Immunology, 2016, 12, 1047-1057.	3.0	33
210	Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis: A 52-week, randomized, single-blind, extension study. Modern Rheumatology, 2018, 28, 20-29.	1.8	33
211	Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting. Annals of the Rheumatic Diseases, 2021, 80, 1130-1136.	0.9	33
212	?1 integrin-mediated signaling induces intercellular adhesion molecule 1 and Fas on rheumatoid synovial cells and Fas-mediated apoptosis. Arthritis and Rheumatism, 2003, 48, 1239-1248.	6.7	32
213	B cell phenotypes, signaling and their roles in secretion of antibodies in systemic lupus erythematosus. Clinical Immunology, 2018, 186, 21-25.	3.2	32
214	Use of mesenchymal stem cells seeded on the scaffold in articular cartilage repair. Inflammation and Regeneration, 2018, 38, 4.	3.7	32
215	Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission. Modern Rheumatology, 2008, 18, 460-464.	1.8	32
216	Baricitinib for the treatment of rheumatoid arthritis and systemic lupus erythematosus: a 2019 update. Expert Review of Clinical Immunology, 2019, 15, 693-700.	3.0	31

#	Article	IF	Citations
217	RANKL as a therapeutic target of rheumatoid arthritis. Journal of Bone and Mineral Metabolism, 2021, 39, 106-112.	2.7	30
218	Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry. Arthritis Research and Therapy, 2022, 24, 61.	3.5	30
219	Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity. Modern Rheumatology, 2012, 22, 814-822.	1.8	29
220	Study on the safety and efficacy of tocilizumab, an anti-IL-6 receptor antibody, in patients with rheumatoid arthritis complicated with AA amyloidosis. Modern Rheumatology, 2014, 24, 405-409.	1.8	29
221	Baricitinib for the treatment of rheumatoid arthritis. Expert Review of Clinical Immunology, 2016, 12, 911-919.	3.0	29
222	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2J). Modern Rheumatology, 2008, 18, 447-454.	1.8	29
223	Clinical characteristics and risk factors forPneumocystis jiroveciipneumonia in patients with rheumatoid arthritis receiving adalimumab: a retrospective review and caseâ€“control study of 17 patients. Modern Rheumatology, 2013, 23, 1085-1093.	1.8	28
224	Overexpression of Peroxiredoxin 4 Affects Intestinal Function in a Dietary Mouse Model of Nonalcoholic Fatty Liver Disease. PLoS ONE, 2016, 11, e0152549.	2.5	28
225	Risk Factors of Hypoglycemia in Patients with Type 2 Diabetes Mellitus: A Study Based on Continuous Glucose Monitoring. Diabetes Technology and Therapeutics, 2018, 20, 603-612.	4.4	28
226	Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan. Arthritis Research and Therapy, 2019, 21, 79.	3.5	28
227	Methionine Commits Cells to Differentiate Into Plasmablasts Through Epigenetic Regulation ofBTBandCNCHomolog 2 by the MethyltransferaseEZH2. Arthritis and Rheumatology, 2020, 72, 1143-1153.	5.6	28
228	Upadacitinib in Rheumatoid Arthritis: A Benefitâ€“Risk Assessment Across a Phase III Program. Drug Safety, 2021, 44, 515-530.	3.2	28
229	Etidronate prevents high dose glucocorticoid induced bone loss in premenopausal individuals with systemic autoimmune diseases. Journal of Rheumatology, 2004, 31, 163-6.	2.0	28
230	Telmisartan at 80 mg/Day Increases High-Molecular-Weight Adiponectin Levels and Improves Insulin Resistance in Diabetic Patients. Advances in Therapy, 2012, 29, 635-644.	2.9	27
231	Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial. Rheumatology, 2014, 53, 904-913.	1.9	27
232	Serum 14-3-3Î· level is associated with severity and clinical outcomes of rheumatoid arthritis, and its pretreatment level is predictive of DAS28 remission with tocilizumab. Arthritis Research and Therapy, 2015, 17, 280.	3.5	27
233	JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical. Modern Rheumatology, 2013, 23, 415-424.	1.8	27
234	Constitutive up-regulation of integrin-mediated adhesion of tumor-infiltrating lymphocytes to osteoblasts and bone marrow-derived stromal cells. Cancer Research, 1998, 58, 4138-45.	0.9	27

#	Article	IF	Citations
235	Treatment strategy based on targeting P-glycoprotein on peripheral lymphocytes in patients with systemic autoimmune disease. Clinical and Experimental Nephrology, 2012, 16, 102-108.	1.6	26
236	Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies. International Journal of Rheumatic Diseases, 2016, 19, 1216-1225.	1.9	26
237	Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naive patients with rheumatoid arthritis: The FIRST Bio study. Modern Rheumatology, 2017, 27, 217-226.	1.8	26
238	Characterization and Changes of Lymphocyte Subsets in Baricitinibâ€Treated Patients With Rheumatoid Arthritis. Arthritis and Rheumatology, 2018, 70, 1923-1932.	5.6	26
239	Glycolaldehyde-modified advanced glycation end-products inhibit differentiation of human monocytes into osteoclasts via upregulation of IL-10. Bone, 2019, 128, 115034.	2.9	26
240	Safety and tolerability of anifrolumab, a monoclonal antibody targeting type I interferon receptor, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study. Modern Rheumatology, 2020, 30, 101-108.	1.8	26
241	Recent progress in treatments of rheumatoid arthritis: an overview of developments in biologics and small molecules, and remaining unmet needs. Rheumatology, 2021, 60, vi12-vi20.	1.9	26
242	The Asia-Pacific League of Associations for Rheumatology consensus statements on the management of systemic lupus erythematosus. Lancet Rheumatology, The, 2021, 3, e517-e531.	3.9	26
243	Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). Modern Rheumatology, 2012, 22, 327-338.	1.8	26
244	Activation signal transduction by Î²1 integrin in T cells from patients with systemic lupus erythematosus. Arthritis and Rheumatism, 2007, 56, 1559-1568.	6.7	25
245	The front line of research into immunoglobin G4-related disease - Do autoantibodies cause immunoglobin G4-related disease?. Modern Rheumatology, 2019, 29, 214-218.	1.8	25
246	Systemic Lupus Erythematosus: Targeted Literature Review of the Epidemiology, Current Treatment, and Disease Burden in the Asia Pacific Region. Arthritis Care and Research, 2022, 74, 187-198.	3.4	25
247	Managing Osteoporosis and Joint Damage in Patients with Rheumatoid Arthritis: An Overview. Journal of Clinical Medicine, 2021, 10, 1241.	2.4	25
248	Human mesenchymal stem cells as a tool for joint repair in rheumatoid arthritis. Clinical and Experimental Rheumatology, 2015, 33, S58-62.	0.8	25
249	Phase II/III Results of a Trial of Antiâ€“Tumor Necrosis Factor Multivalent NANOBODY Compound Ozoralizumab in Patients With Rheumatoid Arthritis. Arthritis and Rheumatology, 2022, 74, 1776-1785.	5.6	25
250	Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activityâ€”results from the ENCOURAGE study, a prospective, international, multicenter randomized study. Modern Rheumatology, 2016, 26, 651-661.	1.8	24
251	The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis. Arthritis Research and Therapy, 2019, 21, 164.	3.5	24
252	Development of the Asia Pacific Lupus Collaboration cohort. International Journal of Rheumatic Diseases, 2019, 22, 425-433.	1.9	24

#	Article	IF	Citations
253	Updated APLAR consensus statements on care for patients with rheumatic diseases during the COVIDâ€19 pandemic. International Journal of Rheumatic Diseases, 2021, 24, 733-745.	1.9	24
254	Efficacy and safety of mizoribine for the treatment of SjÃ¶gren's syndrome: a multicenter open-label clinical trial. Modern Rheumatology, 2007, 17, 464-469.	1.8	24
255	Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2022, 81, 1556-1563.	0.9	24
256	Genome-wide Association Study of Idiopathic Osteonecrosis of the Femoral Head. Scientific Reports, 2017, 7, 15035.	3.3	23
257	Relation Between Hypoglycemia and Glycemic Variability in Type 2 Diabetes Patients with Insulin Therapy: A Study Based on Continuous Glucose Monitoring. Diabetes Technology and Therapeutics, 2018, 20, 140-146.	4.4	23
258	IgG4-related Pleuritis with Elevated Adenosine Deaminase in Pleural Effusion. Internal Medicine, 2018, 57, 2251-2257.	0.7	23
259	Safety and tolerability of sifalimumab, an anti-interferon-Î± monoclonal antibody, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study. Modern Rheumatology, 2020, 30, 93-100.	1.8	23
260	Is It Possible to Withdraw Biologics From Therapy in Rheumatoid Arthritis?. Clinical Therapeutics, 2013, 35, 2028-2035.	2.5	22
261	Validation of different sets of criteria for the diagnosis of SjÃ¶grenâ€™s syndrome in Japanese patients. Modern Rheumatology, 2013, 23, 219-225.	1.8	22
262	Acquiring Chondrocyte Phenotype from Human Mesenchymal Stem Cells under Inflammatory Conditions. International Journal of Molecular Sciences, 2014, 15, 21270-21285.	4.1	22
263	Chemical JAK inhibitors for the treatment of rheumatoid arthritis. Expert Opinion on Pharmacotherapy, 2016, 17, 2215-2225.	1.8	22
264	Enlarged perivascular spaces are associated with the disease activity in systemic lupus erythematosus. Scientific Reports, 2017, 7, 12566.	3.3	22
265	Factors influencing interâ€day glycemic variability in diabetic outpatients receiving insulin therapy. Journal of Diabetes Investigation, 2017, 8, 69-74.	2.4	22
266	Distinctive association of peripheral immune cell phenotypes with capillaroscopic microvascular patterns in systemic sclerosis. Rheumatology, 2019, 58, 2273-2283.	1.9	22
267	Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2019, 78, 890-898.	0.9	22
268	Peficitinib for the treatment of rheumatoid arthritis: an overview from clinical trials. Expert Opinion on Pharmacotherapy, 2020, 21, 1015-1025.	1.8	22
269	Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitis. Arthritis Research and Therapy, 2021, 23, 86.	3.5	22
270	CD45RB expression defines two interconvertible subsets of human CD4+ T cells with memory function. European Journal of Immunology, 1994, 24, 1240-1243.	2.9	21

#	Article	IF	Citations
271	Efficacy and safety of additional use of tacrolimus in patients with early rheumatoid arthritis with inadequate response to DMARDsâ€"a multicenter, double-blind, parallel-group trial. Modern Rheumatology, 2011, 21, 458-468.	1.8	21
272	Local Delivery of Mesenchymal Stem Cells with Poly-Lactic-Co-Glycolic Acid Nano-Fiber Scaffold Suppress Arthritis in Rats. PLoS ONE, 2014, 9, e114621.	2.5	21
273	Adalimumab discontinuation in patients with early rheumatoid arthritis who were initially treated with methotrexate alone or in combination with adalimumab: 1â€...year outcomes of the HOPEFUL-2 study. RMD Open, 2016, 2, e000189.	3.8	21
274	Stopping tumour necrosis factor-targeted biological DMARDs in rheumatoid arthritis. Rheumatology, 2016, 55, ii15-ii22.	1.9	21
275	Association of plasmacytoid dendritic cells with B cell infiltration in minor salivary glands in patients with SjÃ¶gren's syndrome. Modern Rheumatology, 2016, 26, 716-724.	1.8	21
276	Impact of Adalimumab on Work Productivity and Activity Impairment in Japanese Patients with Rheumatoid Arthritis: Large-Scale, Prospective, Single-Cohort ANOUVEAU Study. Advances in Therapy, 2017, 34, 686-702.	2.9	21
277	The JAK inhibitors: do they bring a paradigm shift for the management of rheumatic diseases?. Rheumatology, 2019, 58, i1-i3.	1.9	21
278	Care for patients with rheumatic diseases during COVIDâ€19 pandemic: A position statement from APLAR. International Journal of Rheumatic Diseases, 2020, 23, 717-722.	1.9	21
279	Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan. Arthritis Research and Therapy, 2020, 22, 47.	3.5	21
280	Osteoporosis case ascertainment strategies in European and Asian countries: a comparative review. Osteoporosis International, 2021, 32, 817-829.	3.1	21
281	Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: An overview from clinical trials. Modern Rheumatology, 2022, 32, 1-11.	1.8	21
282	Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity. Modern Rheumatology, 2012, 22, 814-822.	1.8	21
283	The role of chemokines and adhesion molecules in the pathogenesis of rheumatoid arthritis. Drugs of Today, 2001, 37, 477.	2.4	21
284	Disease control by regulation of P-glycoprotein on lymphocytes in patients with rheumatoid arthritis. World Journal of Experimental Medicine, 2015, 5, 225.	1.7	21
285	Multi-trait and cross-population genome-wide association studies across autoimmune and allergic diseases identify shared and distinct genetic component. Annals of the Rheumatic Diseases, 2022, 81, 1301-1312.	0.9	21
286	Usefulness of initial histological features for stratifying Sjogren's syndrome responders to mizoribine therapy. Rheumatology, 2009, 48, 1279-1282.	1.9	20
287	Etanercept overcomes P-glycoprotein-induced drug resistance in lymphocytes of patients with intractable rheumatoid arthritis. Modern Rheumatology, 2010, 20, 139-146.	1.8	20
288	No increased mortality in patients with rheumatoid arthritis treated with biologics: results from the biologics register of six rheumatology institutes in Japan. Modern Rheumatology, 2013, 23, 945-952.	1.8	20

#	Article	IF	Citations
289	Rationale and design of Diabetes Prevention with active Vitamin D (DPVD): a randomised, double-blind, placebo-controlled study. BMJ Open, 2016, 6, e011183.	1.9	20
290	In vitro pharmacological effects of peficitinib on lymphocyte activation: a potential treatment for systemic sclerosis with JAK inhibitors. Rheumatology, 2020, 59, 1957-1968.	1.9	20
291	Eldecalcitol is superior to alfacalcidol in maintaining bone mineral density in glucocorticoid-induced osteoporosis patients (e-GLORIA). Journal of Bone and Mineral Metabolism, 2020, 38, 522-532.	2.7	20
292	Fragmented Hyaluronan Induces Transcriptional Up-regulation of the Multidrug Resistance-1 Gene in CD4+ T Cells. Journal of Biological Chemistry, 2006, 281, 38089-38097.	3.4	19
293	Relevance of lymphocyte subsets to B cellâ€targeted therapy in systemic lupus erythematosus. International Journal of Rheumatic Diseases, 2015, 18, 208-218.	1.9	19
294	Discontinuation of tofacitinib after achieving low disease activity in patients with rheumatoid arthritis: a multicentre, observational study. Rheumatology, 2017, 56, 1293-1301.	1.9	19
295	Determinants of Patientâ€™s Global Assessment of Disease Activity and Physicianâ€™s Global Assessment of Disease Activity in patients with rheumatoid arthritis: A post hoc analysis of overall and Japanese results from phase 3 clinical trials. Modern Rheumatology, 2018, 28, 960-967.	1.8	19
296	Significance of nailfold videocapillaroscopy in patients with idiopathic inflammatory myopathies. Rheumatology, 2019, 58, 120-130.	1.9	19
297	Human dendritic cell-derived osteoclasts with high bone resorption capacity and T cell stimulation ability. Bone, 2021, 142, 115616.	2.9	19
298	An enhanced mitochondrial function through glutamine metabolism in plasmablast differentiation in systemic lupus erythematosus. Rheumatology, 2022, 61, 3049-3059.	1.9	19
299	Genome-wide linkage analysis of type 2 diabetes mellitus reconfirms the susceptibility locus on 11p13â€“p12 in Japanese. Journal of Human Genetics, 2004, 49, 629-634.	2.3	18
300	Treatment of Inflammatory Immunologic Disease 4. B Cell Targeting Therapy Using the Anti-CD20 Antibody Rituximab in Inflammatory Autoimmune Diseases. Internal Medicine, 2007, 46, 1313-1315.	0.7	18
301	Clinical characteristics and risk factors for Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis receiving adalimumab: a retrospective review and caseâ€“control study of 17 patients. Modern Rheumatology, 2013, 23, 1085-93.	1.8	18
302	Low levels of 1,5-anhydro-D-glucitol are associated with vascular endothelial dysfunction in type 2 diabetes. Cardiovascular Diabetology, 2014, 13, 99.	6.8	18
303	Lymphocyte phenotype and its application to precision medicine in systemic autoimmune diseasesâœ°. Seminars in Arthritis and Rheumatism, 2019, 48, 1146-1150.	3.4	18
304	Validity of claimsâ€based algorithms for selected cancers in Japan: Results from the VALIDATEâ€J study. Pharmacoepidemiology and Drug Safety, 2021, 30, 1153-1161.	1.9	18
305	Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritisâ€”a comprehensive review. Arthritis Research and Therapy, 2021, 23, 3.	3.5	18
306	Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2022, 81, 1267-1272.	0.9	18

#	Article	IF	Citations
307	Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinib. Expert Opinion on Pharmacotherapy, 2014, 15, 103-113.	1.8	17
308	A multi-biomarker disease activity score tracks clinical response consistently in patients with rheumatoid arthritis treated with different anti-tumor necrosis factor therapies: A retrospective observational study. Modern Rheumatology, 2015, 25, 344-349.	1.8	17
309	Anti-PD-1 Antibody Therapy Induces Hashimoto's Disease with an Increase in Peripheral Blood Follicular Helper T Cells. Thyroid, 2017, 27, 1335-1336.	4.5	17
310	A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: Results of the 12-week double-blind period. Modern Rheumatology, 2018, 28, 76-84.	1.8	17
311	<scp>l</scp>-Leucine influx through Slc7a5 regulates inflammatory responses of human B cells via mammalian target of rapamycin complex 1 signaling. Modern Rheumatology, 2019, 29, 885-891.	1.8	17
312	Safety and effectiveness of abatacept in Japanese non-elderly and elderly patients with rheumatoid arthritis in an all-cases post-marketing surveillance. Modern Rheumatology, 2019, 29, 747-755.	1.8	17
313	Effectiveness and safety of hydroxychloroquine therapy with or without corticosteroid in patients with systemic lupus erythematosus. International Journal of Rheumatic Diseases, 2019, 22, 434-442.	1.9	17
314	Immunophenotype involved in IgG4-related disease. Modern Rheumatology, 2019, 29, 226-230.	1.8	17
315	Sarilumab monotherapy or in combination with non-methotrexate disease-modifying antirheumatic drugs in active rheumatoid arthritis: A Japan phase 3 trial (HARUKA). Modern Rheumatology, 2020, 30, 239-248.	1.8	17
316	First external validation of sensitivity and specificity of the European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for idiopathic inflammatory myopathies with a Japanese cohort. Annals of the Rheumatic Diseases, 2020, 79, 387-392.	0.9	17
317	Efficacy and Safety of E6011, an Antiâ€Fractalkine Monoclonal Antibody, in Patients With Active Rheumatoid Arthritis With Inadequate Response to Methotrexate: Results of a Randomized, Doubleâ€Blind, Placeboâ€Controlled Phase II Study. Arthritis and Rheumatology, 2021, 73, 587-595.	5.6	17
318	Efficacy and safety of upadacitinib over 84â€‰weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE). Arthritis Research and Therapy, 2021, 23, 9.	3.5	17
319	Estimation of treatment and prognostic factors of pneumocystis pneumonia in patients with connective tissue diseases. RMD Open, 2021, 7, e001508.	3.8	17
320	Differentiation, functions, and roles of T follicular regulatory cells in autoimmune diseases. Inflammation and Regeneration, 2021, 41, 14.	3.7	17
321	Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea. RMD Open, 2021, 7, e001629.	3.8	17
322	â€˜Not at targetâ€™: prevalence and consequences of inadequate disease control in systemic lupus erythematosusâ€”a multinational observational cohort study. Arthritis Research and Therapy, 2022, 24, 70.	3.5	17
323	Severe hypercalcemia and hypernatremia associated with calcipotriol for treatment of psoriasis. Journal of Bone and Mineral Metabolism, 2004, 22, 159-162.	2.7	16
324	Small GTP-binding protein Rho-mediated signaling promotes proliferation of rheumatoid synovial fibroblasts. Arthritis Research, 2005, 7, R476.	2.0	16

#	Article	IF	Citations
325	The REAL database reveals no significant risk of serious infection during treatment with a methotrexate dose of more than 8 mg/week in patients with rheumatoid arthritis. Modern Rheumatology, 2011, 21, 444-448.	1.8	16
326	Dermal mast cell density in fingers reflects severity of skin sclerosis in systemic sclerosis. Modern Rheumatology, 2013, 23, 1151-1157.	1.8	16
327	Histamine inhibits differentiation of skin fibroblasts into myofibroblasts. Biochemical and Biophysical Research Communications, 2015, 463, 434-439.	2.1	16
328	Safety, pharmacokinetics, and pharmacodynamics of epratuzumab in Japanese patients with moderate-to-severe systemic lupus erythematosus: Results from a phase 1/2 randomized study. Modern Rheumatology, 2016, 26, 87-93.	1.8	16
329	Quantitative susceptibility mapping in patients with systemic lupus erythematosus: detection of abnormalities in normal-appearing basal ganglia. European Radiology, 2016, 26, 1056-1063.	4.5	16
330	Evaluation of the alternative classification criteria of systemic lupus erythematosus established by Systemic Lupus International Collaborating Clinics (SLICC). Modern Rheumatology, 2018, 28, 642-648.	1.8	16
331	Efficacy of denosumab with regard to bone destruction in prognostic subgroups of Japanese rheumatoid arthritis patients from the phase II DRIVE study. Rheumatology, 2019, 58, 997-1005.	1.9	16
332	Differential long-term retention of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis by age group from the FIRST registry. Arthritis Research and Therapy, 2020, 22, 136.	3.5	16
333	Tumour necrosis factor alpha promotes secretion of 14-3-3Î· by inducing necroptosis in macrophages. Arthritis Research and Therapy, 2020, 22, 24.	3.5	16
334	Safety and Effectiveness of Peficitinib (ASP015K) in Patients with Rheumatoid Arthritis: Final Results (32 Months of Mean Peficitinib Treatment) From a Long-Term, Open-Label Extension Study in Japan, Korea, and Taiwan. Rheumatology and Therapy, 2021, 8, 425-442.	2.3	16
335	Abatacept therapy reduces CD28+CXCR5+ follicular helper-like T cells in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology, 2017, 35, 562-570.	0.8	16
336	Induction of expression of MHC-class-II antigen on human thyroid carcinoma by wild-type p53. , 1998, 75, 391-395.		15
337	Overcoming treatment unresponsiveness mediated by P-glycoprotein overexpression on lymphocytes in refractory active systemic lupus erythematosus. Modern Rheumatology, 2005, 15, 28-32.	1.8	15
338	Attempt to correct abnormal signal transduction in T lymphocytes from systemic lupus erythematosus patients. Autoimmunity Reviews, 2006, 5, 143-144.	5.8	15
339	Enhanced effect of high-dose leukocytapheresis using a large filter in rheumatoid arthritis. Modern Rheumatology, 2007, 17, 481-485.	1.8	15
340	Effects of raloxifene on lipid and bone metabolism in postmenopausal women with type 2 diabetes. Journal of Bone and Mineral Metabolism, 2013, 31, 89-95.	2.7	15
341	A case of multiple brown tumors with primary hyperparathyroidism. Journal of Bone and Mineral Metabolism, 2013, 31, 123-127.	2.7	15
342	Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors. Modern Rheumatology, 2014, 24, 399-404.	1.8	15

#	Article	IF	Citations
343	Intensive Intervention Can Lead to a Treatment Holiday from Biological DMARDs in Patients with Rheumatoid Arthritis. Drugs, 2014, 74, 2129-2139.	10.9	15
344	Efficacy and safety of abatacept in routine care of patients with rheumatoid arthritis: Orencia^{Â®}as Biological Intensive Treatment for RA (ORBIT) study. Modern Rheumatology, 2014, 24, 754-762.	1.8	15
345	Analysis of bone metabolism during early stage and clinical benefits of early intervention with alendronate in patients with systemic rheumatic diseases treated with high-dose glucocorticoid: Early Diagnosis and Treatment of OsteopoRosis in Japan (EDITOR-J) study. Journal of Bone and Mineral Metabolism, 2016, 34, 646-654.	2.7	15
346	Emerging Role of Fractalkine in the Treatment of Rheumatic Diseases . ImmunoTargets and Therapy, 2020, Volume 9, 241-253.	5.8	15
347	Interleukin-23 drives expansion of Thelper 17 cells through epigenetic regulation by signal transducer and activators of transcription 3 in lupus patients. Rheumatology, 2020, 59, 3058-3069.	1.9	15
348	The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan. Drug Safety, 2021, 44, 711-722.	3.2	15
349	Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials. Annals of the Rheumatic Diseases, 2022, 81, 962-969.	0.9	15
350	Interleukinâ€4 induces proliferation of adult Tâ€cell leukemia cells. European Journal of Haematology, 1993, 50, 133-140.	2.2	14
351	The risk of serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors decreased over time: a report from the registry of Japanese rheumatoid arthritis patients on biologics for long-term safety (REAL) database. Rheumatology International, 2014, 34, 1729-1736.	3.0	14
352	Detrimental effects of high-fat diet loading on vascular endothelial function and therapeutic efficacy of ezetimibe and statins in patients with type 2 diabetes. Endocrine Journal, 2016, 63, 431-440.	1.6	14
353	Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice. Modern Rheumatology, 2016, 26, 850-856.	1.8	14
354	DMARD de-escalation â€" let the patient guide you. Nature Reviews Rheumatology, 2017, 13, 637-638.	8.0	14
355	Relationship between disease activity and patient-reported outcomes in rheumatoid arthritis: Post hoc analyses of overall and Japanese results from two phase 3 clinical trials. Modern Rheumatology, 2018, 28, 950-959.	1.8	14
356	Relevance of P-glycoprotein on CXCR4⁺B cells to organ manifestation in highly active rheumatoid arthritis. Modern Rheumatology, 2018, 28, 276-286.	1.8	14
357	Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis. RMD Open, 2019, 5, e000898.	3.8	14
358	Safety and efficacy of fostamatinib in rheumatoid arthritis patients with an inadequate response to methotrexate in phase II OSKIRA-ASIA-1 and OSKIRA-ASIA-1X study. Rheumatology, 2021, 60, 2884-2895.	1.9	14
359	Amiselimod, a sphingosine 1-phosphate receptor-1 modulator, for systemic lupus erythematosus: A multicenter, open-label exploratory study. Lupus, 2020, 29, 1902-1913.	1.6	14
360	Predictors of new bone erosion in rheumatoid arthritis patients receiving conventional synthetic disease-modifying antirheumatic drugs: Analysis of data from the DRIVE and DESIRABLE studies. Modern Rheumatology, 2021, 31, 34-41.	1.8	14

#	Article	IF	Citations
361	Immune recognition of lysyl-tRNA synthetase and isoleucyl-tRNA synthetase by anti-OJ antibody-positive sera. Journal of Autoimmunity, 2021, 122, 102680.	6.5	14
362	Prophylaxis against pneumocystis pneumonia in rheumatoid arthritis patients treated with b/tsDMARDs: insights from 3787 cases in the FIRST registry. Rheumatology, 2022, 61, 1831-1840.	1.9	14
363	Overcoming treatment unresponsiveness mediated by P-glycoprotein overexpression on lymphocytes in refractory active systemic lupus erythematosus. Modern Rheumatology, 2005, 15, 28-32.	1.8	14
364	Psoriatic arthritis in Japan: difference in clinical features and approach to precision medicine. Clinical and Experimental Rheumatology, 2016, 34, 49-52.	0.8	14
365	Association of Viral Infection With the Development and Pathogenesis of Systemic Lupus Erythematosus. Frontiers in Medicine, 2022, 9, 849120.	2.6	14
366	Activation of Leukocyte Function-Associated Antigen-1 on Adult T-cell Leukemia Cells. Leukemia and Lymphoma, 1999, 36, 15-23.	1.3	13
367	Inter- and intracellular signaling in secondary osteoporosis. Journal of Bone and Mineral Metabolism, 2003, 21, 61-66.	2.7	13
368	Glycated albumin and cross-linking of CD44 induce scavenger receptor expression and uptake of oxidized LDL in human monocytes. Biochemical and Biophysical Research Communications, 2006, 339, 846-851.	2.1	13
369	Small GTPase Rho signaling is involved in Î²1 integrin-mediated up-regulation of intercellular adhesion molecule 1 and receptor activator of nuclear factor ÎºB ligand on osteoblasts and osteoclast maturation. Biochemical and Biophysical Research Communications, 2007, 356, 279-285.	2.1	13
370	Phenotypic changes of lymphocyte in a patient with IgG4-related disease after corticosteroid therapy. Annals of the Rheumatic Diseases, 2012, 71, 2058-2059.	0.9	13
371	Efficacy of Î±â€glucosidase inhibitors combined with dipeptidylâ€peptidaseâ€4 inhibitor (alogliptin) for glucose fluctuation in patients with typeÂ2 diabetes mellitus by continuous glucose monitoring. Journal of Diabetes Investigation, 2013, 4, 393-398.	2.4	13
372	Antihypertensive and metabolic effects of high-dose olmesartan and telmisartan in type 2 diabetes patients with hypertension. Endocrine Journal, 2013, 60, 563-570.	1.6	13
373	Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy: final results of the randomized GO-FORTH trial. Modern Rheumatology, 2016, 26, 481-490.	1.8	13
374	Clinical Features of Patients with Basedow's Disease and High Serum IgG4 Levels. Internal Medicine, 2017, 56, 1009-1013.	0.7	13
375	Efficacy and safety of intravenous belimumab in Japanese patients with systemic lupus erythematosus: A subgroup analysis of a phase 3 randomized placebo-controlled trial. Modern Rheumatology, 2019, 29, 452-460.	1.8	13
376	Modified- versus immediate-release tofacitinib in Japanese rheumatoid arthritis patients: a randomized, phase III, non-inferiority study. Rheumatology, 2019, 58, 70-79.	1.9	13
377	Comparative study of corticosteroid monotherapy, and TNF inhibitors with or without corticosteroid in patients with refractory entero-Behcetâ€™s disease. Arthritis Research and Therapy, 2019, 21, 151.	3.5	13
378	Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial. Annals of the Rheumatic Diseases, 2020, 79, 94-102.	0.9	13

#	Article	IF	Citations
379	Correlation between serological biomarkers of extracellular matrix turnover and lung fibrosis and pulmonary artery hypertension in patients with systemic sclerosis. International Journal of Rheumatic Diseases, 2020, 23, 532-539.	1.9	13
380	Down-regulation of Î±6 integrin, an anti-oncogene product, by functional cooperation of H-Ras and c-Myc. Genes To Cells, 2001, 6, 337-343.	1.2	12
381	Efficacy of mizoribine treatment in patients with SjÃ¶grenâ€™s syndrome: an open pilot trial. Modern Rheumatology, 2003, 13, 339-345.	1.8	12
382	Safety and Effectiveness of 6 Monthsâ€™ Etanercept Monotherapy and Combination Therapy in Japanese Patients with Rheumatoid Arthritis: Effect of Concomitant Disease-modifying Antirheumatic Drugs. Journal of Rheumatology, 2013, 40, 1658-1668.	2.0	12
383	Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study. Modern Rheumatology, 2014, 24, 725-733.	1.8	12
384	A case of teriparatide-induced severe hypophosphatemia and hypercalcemia. Journal of Bone and Mineral Metabolism, 2014, 32, 601-604.	2.7	12
385	Excess Visceral Adipose Tissue Worsens the Vascular Endothelial Function in Patients with Type 2 Diabetes Mellitus. Internal Medicine, 2016, 55, 3091-3095.	0.7	12
386	Low disease activity for up to 3Âyears after adalimumab discontinuation in patients with early rheumatoid arthritis: 2-year results of the HOPEFUL-3 Study. Arthritis Research and Therapy, 2017, 19, 56.	3.5	12
387	Intracranial vessel wall lesions in patients with systematic lupus erythematosus. Journal of Magnetic Resonance Imaging, 2018, 48, 1237-1246.	3.4	12
388	Comparison of efficacy of TNF inhibitors and abatacept in patients with rheumatoid arthritis; Adjusted with propensity score matching. Clinical Immunology, 2018, 191, 67-74.	3.2	12
389	Effect of subcutaneous tocilizumab treatment on work/housework status in biologic-naÃ¯ve rheumatoid arthritis patients using inverse probability of treatment weighting: FIRST ACT-SC study. Arthritis Research and Therapy, 2018, 20, 151.	3.5	12
390	Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asiaâ€Pacific region: Postâ€hoc analyses of pooled clinical study data. International Journal of Rheumatic Diseases, 2019, 22, 1094-1106.	1.9	12
391	Safety of baricitinib in East Asian patients with moderateâ€toâ€severe active rheumatoid arthritis: An integrated analysis from clinical trials. International Journal of Rheumatic Diseases, 2020, 23, 65-73.	1.9	12
392	Critical roles of super-enhancers in the pathogenesis of autoimmune diseases. Inflammation and Regeneration, 2020, 40, 16.	3.7	12
393	COVIDâ€19 infection in patients with systemic lupus erythematosus: Data from the Asia Pacific Lupus Collaboration. International Journal of Rheumatic Diseases, 2020, 23, 1255-1257.	1.9	12
394	Enhanced Fatty Acid Synthesis Leads to Subset Imbalance and IFN-Î³ Overproduction in T Helper 1 Cells. Frontiers in Immunology, 2020, 11, 593103.	4.8	12
395	Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term studyÂ. Rheumatology, 2021, 60, 2256-2266.	1.9	12
396	Efficacy and safety of additional use of tacrolimus in patients with early rheumatoid arthritis with inadequate response to DMARDsâ€”a multicenter, double-blind, parallel-group trial. Modern Rheumatology, 2011, 21, 458-468.	1.8	12

#	Article	IF	Citations
397	Involvement of lncRNA IL21-AS1 in interleukin-2 and T follicular regulatory cell activation in systemic lupus erythematosus. Arthritis Research and Therapy, 2021, 23, 302.	3.5	12
398	Growth suppression of human mast cells expressing constitutively active c-kit receptors by JNK inhibitor SP600125. Genes To Cells, 2006, 11, 983-992.	1.2	11
399	B cell or T cell-dominant recurrence after rituximab therapy in patients with SLE. Annals of the Rheumatic Diseases, 2012, 71, 1749-1750.	0.9	11
400	Abatacept inhibits radiographic progression in patients with rheumatoid arthritis: a retrospective analysis of 6 months of abatacept treatment in routine clinical practice. The ALTAIR study. Modern Rheumatology, 2014, 24, 42-51.	1.8	11
401	Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study. Modern Rheumatology, 2014, 24, 734-743.	1.8	11
402	Early response to certolizumab pegol predicts long-term outcomes in patients with active rheumatoid arthritis: results from the Japanese studies. Modern Rheumatology, 2015, 25, 11-20.	1.8	11
403	Abatacept in combination with methotrexate in Japanese biologic-naive patients with active rheumatoid arthritis: a randomised placebo-controlled phase IV study. RMD Open, 2018, 4, e000813.	3.8	11
404	Real-World Postmarketing Study of the Impact of Adalimumab Treatment on Work Productivity and Activity Impairment in Patients with Psoriatic Arthritis. Advances in Therapy, 2019, 36, 691-707.	2.9	11
405	A Study of the Vascular Endothelial Function in Patients with Type 2 Diabetes Mellitus and Rheumatoid Arthritis. Internal Medicine, 2019, 58, 1383-1390.	0.7	11
406	Type I and II interferons commit to abnormal expression of chemokine receptor on B cells in patients with systemic lupus erythematosus. Clinical Immunology, 2019, 200, 1-9.	3.2	11
407	Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial. Modern Rheumatology, 2020, 30, 313-320.	1.8	11
408	Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis. Arthritis Research and Therapy, 2020, 22, 115.	3.5	11
409	A phase 2 study of E6011, an anti-Fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to biological disease-modifying antirheumatic drugs. Modern Rheumatology, 2021, 31, 783-789.	1.8	11
410	Prevention of infective complications in systemic lupus erythematosus: A systematic literature review for the APLAR consensus statements. International Journal of Rheumatic Diseases, 2021, 24, 880-895.	1.9	11
411	Suppressive Activity of Interleukin 4 on the Induction of Antigen-specific Cytotoxic T Cells in Humans. Japanese Journal of Cancer Research, 1991, 82, 585-592.	1.7	10
412	Intercellular adhesion molecule 1 underlies the functional heterogeneity of synovial cells in patients with rheumatoid arthritis: Involvement of cell cycle machinery. Arthritis and Rheumatism, 2000, 43, 2513-2522.	6.7	10
413	A case of life-threatening refractory polychondritis successfully treated with combined intensive immunosuppressive therapy with methotrexate. Modern Rheumatology, 2007, 17, 144-147.	1.8	10
414	Role of P-glycoprotein on CD69+CD4+cells in the pathogenesis of proliferative lupus nephritis and non-responsiveness to immunosuppressive therapy. RMD Open, 2017, 3, e000423.	3.8	10

#	Article	IF	Citations
415	The Effects of Pioglitazone on Bone Formation and Resorption Markers in Type 2 Diabetes Mellitus. Internal Medicine, 2017, 56, 1301-1306.	0.7	10
416	Early effects of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes: study based on continuous glucose monitoring. Diabetology and Metabolic Syndrome, 2017, 9, 60.	2.7	10
417	Comparison of effects of anagliptin and alogliptin on serum lipid profile in type 2 diabetes mellitus patients. Journal of Diabetes Investigation, 2018, 9, 360-365.	2.4	10
418	Hyperparathyroidism-jaw Tumor Syndrome Confirmed by Preoperative Genetic Testing. Internal Medicine, 2018, 57, 841-844.	0.7	10
419	Long-term safety and efficacy of weekly subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis who had an inadequate response to subcutaneous tocilizumab every other week: Results from the open-label extension of the SHINOBI study. Modern Rheumatology, 2019, 29, 767-774.	1.8	10
420	Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: A post hoc analysis of clinical trial data. Modern Rheumatology, 2019, 29, 756-766.	1.8	10
421	ASP5094, a humanized monoclonal antibody against integrin alpha-9, did not show efficacy in patients with rheumatoid arthritis refractory to methotrexate: results from a phase 2a, randomized, double-blind, placebo-controlled trial. Arthritis Research and Therapy, 2020, 22, 252.	3.5	10
422	Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation. Arthritis Research and Therapy, 2020, 22, 141.	3.5	10
423	Insensitivity versus poor response to tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective cohort study. Arthritis Research and Therapy, 2020, 22, 41.	3.5	10
424	The additive effects of hydroxychloroquine to maintenance therapy with standard of care in patients with systemic lupus erythematosus. International Journal of Rheumatic Diseases, 2020, 23, 549-558.	1.9	10
425	Similarity of Response to Biologics Between Elderly-onset Rheumatoid Arthritis (EORA) and Non-EORA Elderly Patients: From the FIRST Registry. Journal of Rheumatology, 2021, 48, 1655-1662.	2.0	10
426	Effects of Denosumab in Japanese Patients With Rheumatoid Arthritis Treated With Conventional Antirheumatic Drugs: 36-month Extension of a Phase III Study. Journal of Rheumatology, 2021, 48, 1663-1671.	2.0	10
427	Enhanced effect of high-dose leukocytapheresis using a large filter in rheumatoid arthritis. Modern Rheumatology, 2007, 17, 481-485.	1.8	10
428	Etanercept overcomes P-glycoprotein-induced drug resistance in lymphocytes of patients with intractable rheumatoid arthritis. Modern Rheumatology, 2010, 20, 139-146.	1.8	10
429	Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1). Modern Rheumatology, 2022, 32, 263-272.	1.8	10
430	Efficacy and safety of belimumab during maintenance therapy in patients with systemic lupus erythematosus. Rheumatology, 2022, 61, 3614-3626.	1.9	10
431	Safety and effectiveness of mepolizumab therapy in remission induction therapy for eosinophilic granulomatosis with polyangiitis: a retrospective study. Arthritis Research and Therapy, 2022, 24, .	3.5	10
432	Glucocorticoid-induced osteoporosis: skeletal manifestations of glucocorticoid use and 2004 Japanese Society for Bone and Mineral Research-proposed guidelines for its management. Modern Rheumatology, 2005, 15, 163-168.	1.8	9

#	Article	IF	Citations
433	Successful treatment of primary biliary cirrhosis with etanercept in a patient with rheumatoid arthritis. Joint Bone Spine, 2011, 78, 535-536.	1.6	9
434	Post-hoc analysis showing better clinical response with the loading dose of certolizumab pegol in Japanese patients with active rheumatoid arthritis. Modern Rheumatology, 2016, 26, 473-480.	1.8	9
435	Podocyte and endothelial cell injury lead to nephrotic syndrome in proliferative lupus nephritis. Histopathology, 2018, 72, 1084-1092.	2.9	9
436	The role of nailfold videocapillaroscopy in patients with systemic sclerosis. Immunological Medicine, 2018, 41, 113-119.	2.6	9
437	The Effects of Mitiglinide and Repaglinide on Postprandial Hyperglycemia in Patients Undergoing Methylprednisolone Pulse Therapy. Internal Medicine, 2018, 57, 65-70.	0.7	9
438	Efficacy of once-weekly teriparatide in patients with glucocorticoid-induced osteoporosis: the TOWER-GO study. Journal of Bone and Mineral Metabolism, 2021, 39, 446-455.	2.7	9
439	Long-term safety and efficacy of sirukumab for patients with rheumatoid arthritis who previously received sirukumab in randomised controlled trials (SIRROUND-LTE). RMD Open, 2021, 7, e001465.	3.8	9
440	Clinical relevance of T follicular helper cells in systemic lupus erythematosus. Expert Review of Clinical Immunology, 2021, 17, 1143-1150.	3.0	9
441	Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: results from BE ACTIVE. Rheumatology, 2023, 62, 617-628.	1.9	9
442	Differential Expression of Integrins Î±6 and Î±4 Determines Pathways in Human Peripheral CD4+ T Cell Differentiation. Cell Adhesion and Communication, 1994, 2, 403-415.	1.7	8
443	Constitutive activation of LIL-Stat in adult T-cell leukemia cells. Blood, 2000, 95, 2715-2718.	1.4	8
444	Assessment of Risks of Pulmonary Infection During 12 Months Following Immunosuppressive Treatment for Active Connective Tissue Diseases: A Large-scale Prospective Cohort Study. Journal of Rheumatology, 2015, 42, 614-622.	2.0	8
445	Efficacy of linagliptin and teneligliptin for glycemic control in type 2 diabetic patients with chronic kidney disease: assessment by continuous glucose monitoring; a pilot study. Diabetology International, 2016, 7, 368-374.	1.4	8
446	Clinically relevant radiographic progression in joint destruction in RA patients with abnormal MMP-3 or high levels of CRP despite 1-year treatment with infliximab. Modern Rheumatology, 2016, 26, 807-812.	1.8	8
447	Determinants of hemoglobin A1c level in patients with type 2 diabetes after inâ€hospital diabetes education: A study based on continuous glucose monitoring. Journal of Diabetes Investigation, 2017, 8, 314-320.	2.4	8
448	Twentyâ€fourâ€hour variations in blood glucose level in Japanese type 2 diabetes patients based on continuous glucose monitoring. Journal of Diabetes Investigation, 2018, 9, 75-82.	2.4	8
449	Fifty-Two-Week Results of Clinical and Imaging Assessments of a Patient with Rheumatoid Arthritis Complicated by Systemic Sclerosis with Interstitial Pneumonia and Type 1 Diabetes despite Multiple Disease-Modifying Antirheumatic Drug Therapy That Was Successfully Treated with Baricitinib: A Novel Case Report. Case Reports in Rheumatology, 2019, 2019, 1-5.	0.6	8
450	Evaluation of oxygen extraction fraction in systemic lupus erythematosus patients using quantitative susceptibility mapping. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 1648-1658.	4.3	8

#	Article	IF	Citations
451	Identifying the preferable rheumatoid arthritis subgroups for intervention with the anti-RANKL antibody denosumab to reduce progression of joint destruction. RMD Open, 2020, 6, e001249.	3.8	8
452	Clinical aspects in patients with rheumatoid arthritis complicated with lymphoproliferative disorders without regression after methotrexate withdrawal and treatment for arthritis after regression of lymphoproliferative disorders. Modern Rheumatology, 2021, 31, 94-100.	1.8	8
453	Digital pitting scars are associated with a severe disease course and death in systemic sclerosis: a study from the EUSTAR cohort. Rheumatology, 2022, 61, 1141-1147.	1.9	8
454	Dermal mast cell density in fingers reflects severity of skin sclerosis in systemic sclerosis. Modern Rheumatology, 2013, 23, 1151-7.	1.8	8
455	Adult-Onset Idiopathic Progressive Acro-Osteolysis With Proximal Symphalangism. Journal of Bone and Mineral Research, 2003, 19, 165-167.	2.8	7
456	Prevention of joint destruction by tacrolimus in patients with early rheumatoid arthritis: a post hoc analysis of a double-blind, randomized, placebo-controlled study. Modern Rheumatology, 2013, 23, 1045-1052.	1.8	7
457	Usefulness of nailfold videocapillaroscopy for systemic sclerosis. Inflammation and Regeneration, 2016, 36, 5.	3.7	7
458	Evaluation of golimumab for the treatment of patients with active rheumatoid arthritis. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 319-326.	3.3	7
459	Efficacy and safety of tabalumab plus standard of care in Japanese patients with active systemic lupus erythematosus: Subgroup analyses of the ILLUMINATE-1 study. Modern Rheumatology, 2017, 27, 284-291.	1.8	7
460	Association Between Diabetic Microangiopathies and Glycemic Variability Assessed by Continuous Glucose Monitoring. Journal of UOEH, 2018, 40, 11-18.	0.6	7
461	Effectiveness and safety of initiating adalimumab plus â‰¥12â€‰mg/week methotrexate with adjustable dosing in biologic-naÃ¯ve patients with early rheumatoid arthritis: HAWK study postmarketing surveillance in Japan. Modern Rheumatology, 2019, 29, 572-580.	1.8	7
462	Validity and responsiveness of the Work Functioning Impairment Scale (WFun) in rheumatoid arthritis patients: A multicenter prospective study. Modern Rheumatology, 2020, 30, 821-827.	1.8	7
463	Is precision medicine possible in rheumatic diseases? Lessons from selective use of targeted therapies in patients with psoriatic arthritis. Expert Review of Clinical Immunology, 2020, 16, 199-206.	3.0	7
464	Treatment of rheumatoid arthritis after regression of lymphoproliferative disorders in patients treated with methotrexate: a retrospective, multi-center descriptive study. Modern Rheumatology, 2022, 32, 41-49.	1.8	7
465	Five Cases of IgG4-related Disease with Nasal Mucosa and Sinus Involvement. Internal Medicine, 2020, 59, 1905-1911.	0.7	7
466	Associations between urinary 6â€sulfatoxymelatonin excretion and diabetic vascular complications or arteriosclerosis in patients with typeÂ2 diabetes. Journal of Diabetes Investigation, 2021, 12, 601-609.	2.4	7
467	Pathological role of activated mTOR in CXCR3+ memory B cells of rheumatoid arthritis. Rheumatology, 2021, 60, 5452-5462.	1.9	7
468	Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis. Arthritis Research and Therapy, 2021, 23, 221.	3.5	7

#	Article	IF	Citations
469	Hypoglycemia induces vascular endothelial dysfunction in subjects with normal glucose tolerance. Scientific Reports, 2022, 12, 2598.	3.3	7
470	A patient with eosinophilic granulomatosis with polyangiitis successfully weaned from corticosteroids through remission induction therapy with mepolizumab. Modern Rheumatology Case Reports, 2022, 6, 243-247.	0.7	7
471	Antiviral and Antiproliferative Activities of Recombinant Human Interferon Î±2, Î² and Î³ on HTLV-â... and ATL Cells <i>in Vitro</i>. Journal of UOEH, 1990, 12, 149-161.	0.6	6
472	Structural damages disturb functional improvement in patients with rheumatoid arthritis treated with etanercept. Modern Rheumatology, 2012, 22, 186-194.	1.8	6
473	Prevention of joint destruction in patients with high disease activity or high C-reactive protein levels: Post hoc analysis of the GO-FORTH study. Modern Rheumatology, 2016, 26, 323-330.	1.8	6
474	Fatal Chronic Active Epstein-Barr Virus Infection in a Rheumatoid Arthritis Patient Treated with Abatacept. Internal Medicine, 2019, 58, 585-591.	0.7	6
475	The development of quality indicators for systemic lupus erythematosus using electronic health data: A modified RAND appropriateness method. Modern Rheumatology, 2020, 30, 525-531.	1.8	6
476	The approach to precision medicine for the treatment of psoriatic arthritis. Immunological Medicine, 2020, 43, 98-102.	2.6	6
477	A pooled safety analysis of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis treated over a median of 2 years. Modern Rheumatology, 2021, 31, 543-555.	1.8	6
478	Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: Subgroup analyses of a global phase 3 study (FINCH 2). Modern Rheumatology, 2022, 32, 59-67.	1.8	6
479	Response to tocilizumab and work productivity in patients with rheumatoid arthritis: 2-year follow-up of FIRST ACT-SC study. Modern Rheumatology, 2021, 31, 42-52.	1.8	6
480	Comparative Efficacy and Safety of Peficitinib Versus Tofacitinib and Baricitinib for Treatment of Rheumatoid Arthritis: A Systematic Review and Network Meta-Analysis. Rheumatology and Therapy, 2021, 8, 729-750.	2.3	6
481	Serum TNFÎ± levels at 24 h after certolizumab pegol predict effectiveness at week 12 in patients with rheumatoid arthritis from TSUBAME study. Arthritis Research and Therapy, 2021, 23, 154.	3.5	6
482	Low Vitamin D Levels are Associated with Vascular Endothelial Dysfunction in Patients with Poorly Controlled Type 2 Diabetes: A Retrospective Study. Journal of Atherosclerosis and Thrombosis, 2022, 29, 242-251.	2.0	6
483	Jak and Syk: Emerging their relevance to the treatment of inflammatory diseases. Inflammation and Regeneration, 2011, 31, 237-244.	3.7	6
484	Human urinary trypsin inhibitor bolus infusion improved severe interstitial pneumonia in mixed connective tissue disease. Modern Rheumatology, 2005, 15, 374-380.	1.8	6
485	Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan study. Clinical and Experimental Rheumatology, 2020, 38, 848-857.	0.8	6
486	Rituximab in the real-world treatment of lupus nephritis: A retrospective cohort study in Japan. Modern Rheumatology, 2023, 33, 145-153.	1.8	6

#	Article	IF	Citations
487	Inhibitory Effect of IL-1 on the TSH Dependent Growth of Rat Thyroid Cells (FRTL-5).. Endocrinologia Japonica, 1990, 37, 619-627.	0.5	5
488	Suppressive effect of interleukin-4 on the differentiation of M1 and HL60 myeloid leukemic cells. Journal of Leukocyte Biology, 1993, 54, 133-137.	3.3	5
489	Human urinary trypsin inhibitor bolus infusion improved severe interstitial pneumonia in mixed connective tissue disease. Modern Rheumatology, 2005, 15, 374-380.	1.8	5
490	Effects of pravastatin, atorvastatin, and rosuvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia. Diabetology International, 2013, 4, 117-125.	1.4	5
491	Comparative analysis of the effects of alogliptin and vildagliptin on glucose metabolism in type 2 diabetes mellitus. Endocrine Journal, 2017, 64, 179-189.	1.6	5
492	Economic impact of adalimumab treatment in Japanese patients with rheumatoid arthritis from the adalimumab non-interventional trial for up-verified effects and utility (ANOUVEAU) study. Modern Rheumatology, 2018, 28, 39-47.	1.8	5
493	Clinical efficacy, radiographic, and safety results of golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior therapy with disease-modifying antirheumatic drugs: Final results of the GO-MONO trial through week 120. Modern Rheumatology, 2018, 28, 770-779.	1.8	5
494	Baricitinib for systemic lupus erythematosus â€“ Authors' reply. Lancet, The, 2019, 393, 402-403.	13.7	5
495	Hypoglycemia Abrogates the Vascular Endothelial Protective Effect of Exenatide in Type 2 Diabetes Mellitus. Diabetes Therapy, 2019, 10, 1127-1132.	2.5	5
496	Mediastinal and axillar lymphadenopathy in patients with rheumatoid arthritis: prevalence and clinical significance. Clinical Imaging, 2019, 55, 140-143.	1.5	5
497	Skeletal unloading reduces cluster of differentiation (CD) 38 expression in the bone marrow and osteoblasts of mice. Journal of Orthopaedic Science, 2020, 25, 331-337.	1.1	5
498	Impaired expression of innate immunity-related genes in IgG4-related disease: A possible mechanism in the pathogenesis of IgG4-RD. Modern Rheumatology, 2020, 30, 551-557.	1.8	5
499	5-year remission rate after the discontinuation of adalimumab in patients with rheumatoid arthritis: Long-term follow-up results of the HONOR study. Modern Rheumatology, 2020, 30, 799-806.	1.8	5
500	Changes in endothelial function during educational hospitalization and the contributor to improvement of endothelial function in type 2 diabetes mellitus. Scientific Reports, 2020, 10, 15384.	3.3	5
501	Severe pulmonary arterial hypertension and interstitial pneumonia related to systemic lupus erythematosus successfully treated with mycophenolate mofetil: A novel case report. Lupus, 2020, 29, 1955-1960.	1.6	5
502	Enlarged glycemic variability in sulfonylurea-treated well-controlled type 2 diabetics identified using continuous glucose monitoring. Scientific Reports, 2021, 11, 4875.	3.3	5
503	Relationship between glycemic intraday variations evaluated in continuous glucose monitoring and HbA1c variability in type 2 diabetes: pilot study. Diabetology and Metabolic Syndrome, 2021, 13, 45.	2.7	5
504	Radiographic Progression of Structural Joint Damage Over 5 Years of Baricitinib Treatment in Patients With Rheumatoid Arthritis: Results From RA-BEYOND. Journal of Rheumatology, 2022, 49, 133-141.	2.0	5

#	Article	IF	Citations
505	Glucocorticoid-induced osteoporosis: skeletal manifestations of glucocorticoid use and 2004 Japanese Society for Bone and Mineral Research-proposed guidelines for its management. Modern Rheumatology, 2005, 15, 163-168.	1.8	5
506	Pancreas-protective effect of rituximab for acute-onset type 1 diabetes in the honeymoon period: a case report. Endocrinology, Diabetes and Metabolism Case Reports, 2016, 2016, 160020.	0.5	5
507	Chemokine and Cellular Adhesion in the Context of Heparan Sulfate Proteoglycan.. Trends in Glycoscience and Glycotechnology, 1998, 10, 153-160.	0.1	5
508	Apremilast in a Japanese subgroup with BehÃ§etâ€™s syndrome: Results from a Phase 3, randomised, double-blind, placebo-controlled study. Modern Rheumatology, 2022, 32, 413-421.	1.8	5
509	Risk Factor Analysis for Type 2 Diabetes Patients About Hypoglycemia Using Continuous Glucose Monitoring: Results from a Prospective Observational Study. Diabetes Technology and Therapeutics, 2022, 24, 435-445.	4.4	5
510	Pathological relevance and treatment perspective of JAK targeting in systemic lupus erythematosus. Expert Review of Clinical Immunology, 2022, , .	3.0	5
511	Increased remodelling of interstitial collagens and basement membrane is suppressed by treatment in patients with rheumatoid arthritis: serological evaluation of a one-year prospective study of 149 Japanese patients. Clinical and Experimental Rheumatology, 2018, 36, 462-470.	0.8	5
512	Difficult-to-treat rheumatoid arthritis with respect to responsiveness to biologic/targeted synthetic DMARDs: a retrospective cohort study from the FIRST registry. Clinical and Experimental Rheumatology, 2022, 40, 86-96.	0.8	5
513	Eosinophilic granulomatosis with polyangiitis exhibits T cell activation and IgG4 immune response in the tissue; comparison with IgG4-related disease. RMD Open, 2022, 8, e002086.	3.8	5
514	Usefulness of ultrasound as a predictor of elderly-onset rheumatoid arthritis with polymyalgia rheumatica-like onset. Modern Rheumatology, 2023, 33, 318-322.	1.8	5
515	Nailfold microvascular abnormalities are associated with a higher prevalence of pulmonary arterial hypertension in patients with MCTD. Rheumatology, 2022, 61, 4875-4884.	1.9	5
516	Associations between continuous glucose monitoring-derived metrics and HbA1c in patients with type 2 diabetes mellitus. Diabetes Research and Clinical Practice, 2022, 186, 109836.	2.8	5
517	Impact of serum interleukin-22 as a biomarker for the differential use of molecular targeted drugs in psoriatic arthritis: a retrospective study. Arthritis Research and Therapy, 2022, 24, 86.	3.5	5
518	Bâ€Ð Cell Interactions in the Spontaneous Activation of B Cells in Autoimmune NZB Mice. Microbiology and Immunology, 1991, 35, 741-753.	1.4	4
519	A case of catastrophic antiphospholipid antibody syndrome complicated with systemic lupus erythematosus, double positive for anti-cardiolipin/Î²2 glycoprotein I and anti-phosphatidylserine/prothrombin autoantibodies. Modern Rheumatology, 2012, 22, 769-773.	1.8	4
520	Successful treatment of osteomalacia caused by renal tubular acidosis associated with SjÃ¶grenâ€™s syndrome. Modern Rheumatology, 2013, 23, 401-405.	1.8	4
521	Efficacy and safety of reducing duration of infliximab infusion. Modern Rheumatology, 2014, 24, 275-280.	1.8	4
522	Combination therapy for early rheumatoid arthritis: a treatment holiday perspective. Expert Review of Clinical Pharmacology, 2015, 8, 115-122.	3.1	4

#	Article	IF	Citations
523	Remission induction by Raising the dose of Remicade in RA (RRRR) study: Rationale and study protocol for a randomized controlled trial comparing for sustained clinical remission after discontinuation of infliximab in patients with rheumatoid arthritis. Contemporary Clinical Trials Communications, 2017, 8, 49-54.	1.1	4
524	A case of rheumatoid arthritis treated with infliximab who developed disseminated Penicillium marneffei infection after visit to Thailand. Modern Rheumatology Case Reports, 2017, 1, 43-48.	0.7	4
525	Regulatory Mechanism of The Induction of Regulatory T Cells through Growth Factors Released by Human Mesenchymal Stem Cells. Critical Reviews in Immunology, 2018, 38, 471-478.	0.5	4
526	Successful Management of Pregnancy in a Patient with Systemic Lupus Erythematosus-associated Pulmonary Arterial Hypertension. Internal Medicine, 2018, 57, 1655-1659.	0.7	4
527	An Autopsy Case with Cerebral Hemorrhaging due to disseminated Aspergillosis During Glucocorticoid Therapy for Overlap Syndrome of Systemic Lupus Erythematosus and Systemic Sclerosis. Internal Medicine, 2019, 58, 1023-1027.	0.7	4
528	Usefulness of hemoglobin A1c and glycated albumin measurements for insulinoma screening: an observational case-control study. BMC Cancer, 2019, 19, 174.	2.6	4
529	Relationship between interstitial glucose variability in ambulatory glucose profile and standardized continuous glucose monitoring metrics; a pilot study. Diabetology and Metabolic Syndrome, 2020, 12, 70.	2.7	4
530	Factors associated with successful discontinuation of certolizumab pegol in early rheumatoid arthritis. International Journal of Rheumatic Diseases, 2020, 23, 316-324.	1.9	4
531	Rapidly progressive glomerulonephritis after introduction of certolizumab pegol: a case report. Modern Rheumatology Case Reports, 2021, 5, 11-15.	0.7	4
532	A case of systemic lupus erythematosus with marked ascites due to idiopathic non-cirrhotic portal hypertension. Modern Rheumatology Case Reports, 2021, 5, 285-291.	0.7	4
533	Stimulator of Interferon Genes-associated Vasculopathy with an Onset in Infancy Diagnosed after the Development of Atypical Pulmonary Lesions During Treatment as Juvenile Idiopathic Arthritis. Internal Medicine, 2021, 60, 1109-1114.	0.7	4
534	Blood glucose dynamics during sleep in patients with obstructive sleep apnea and normal glucose tolerance: effects of CPAP therapy. Sleep and Breathing, 2022, 26, 771-781.	1.7	4
535	Sarilumab monotherapy vs sarilumab and methotrexate combination therapy in patients with rheumatoid arthritis. Rheumatology, 2022, 61, 2596-2602.	1.9	4
536	IgG4-type Multiple Myeloma with Diffuse Enlargement of the Thyroid Requiring Differentiation from IgG4-related Disease. Internal Medicine, 2020, 59, 711-714.	0.7	4
537	mTOR activation in CD8+ cells contributes to disease activity of rheumatoid arthritis and increases therapeutic response to TNF inhibitors. Rheumatology, 2021, , .	1.9	4
538	Benefitâ€“Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis. Rheumatology and Therapy, 2022, 9, 191-206.	2.3	4
539	Clinical, radiographic and functional efficacy of abatacept in routine care for rheumatoid arthritis patients: Abatacept Leading Trial for RA on Imaging Remission (ALTAIR) study. Clinical and Experimental Rheumatology, 2016, 34, 834-841.	0.8	4
540	Anti-CD20 and other novel biotherapies for systemic lupus erythematosus. APLAR Journal of Rheumatology, 2006, 9, 413-418.	0.2	3

#	Article	IF	Citations
541	Effect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals: Post Hoc Analysis of Japanese Patients (MELODY Study). Rheumatology and Therapy, 2016, 3, 129-141.	2.3	3
542	Efficacy and safety of sirukumab in Japanese patients with moderate to severe rheumatoid arthritis inadequately controlled by disease modifying anti-rheumatic drugs: Subgroup analysis of a phase 3 study. Modern Rheumatology, 2018, 28, 941-949.	1.8	3
543	Effects of hypergravity on the gene expression of the hypothalamic feeding-related neuropeptides in mice via vestibular inputs. Peptides, 2018, 105, 14-20.	2.4	3
544	A Case of Marine-Lenhart Syndrome with Predominance of Plummer Disease. Journal of UOEH, 2019, 41, 165-170.	0.6	3
545	Addition of canagliflozin to insulin improves glycaemic control and reduces insulin dose in patients with type 2 diabetes mellitus: A randomized controlled trial. Diabetes, Obesity and Metabolism, 2019, 21, 2174-2179.	4.4	3
546	Optimal Biologic Selection for Treatment of Psoriatic Arthritis: the Approach to Precision Medicine. Current Rheumatology Reports, 2019, 21, 21.	4.7	3
547	THU0193â€…EFFICACY OF TOFACITINIB MONOTHERAPY, TOFACITINIB WITH METHOTREXATE AND ADALIMUMAB WITH METHOTREXATE IN PATIENTS WITH EARLY (â‰2 YEARS) VS ESTABLISHED (>2 YEARS) RHEUMATOID ARTHRITIS: A POST HOC ANALYSIS OF DATA FROM ORAL STRATEGY. , 2019, , .		3
548	Small Cell Lung Cancer Patient with Anti-transcriptional Intermediary Factor 1Î³ Antibody Who Developed Dermatomyositis after Successful Chemoradiotherapy. Internal Medicine, 2019, 58, 427-431.	0.7	3
549	Efficacy and safety of sirukumab in Japanese patients with active rheumatoid arthritis who were refractory or intolerant to anti-tumor necrosis factor therapy: Subgroup analysis of a randomized, double-blind, multicenter, phase 3 study (SIRROUND-T). Modern Rheumatology, 2019, 29, 306-313.	1.8	3
550	Potential of B-cell-targeting therapy in overcoming multidrug resistance and tissue invasiveness associated with P-glycoprotein expressing-B cell compartments. Immunological Medicine, 2020, 44, 1-10.	2.6	3
551	A wide perspective of targeted therapies for precision medicine in autoimmune diseases. Expert Review of Precision Medicine and Drug Development, 2020, 5, 447-453.	0.7	3
552	Usefulness of the index calculated as the product of levels of fasting plasma glucose and hemoglobin A1c for insulinoma screening. Endocrine Journal, 2020, 67, 509-513.	1.6	3
553	Minodronate combined with alfacalcidol versus alfacalcidol alone for glucocorticoid-induced osteoporosis: a multicenter, randomized, comparative study. Journal of Bone and Mineral Metabolism, 2020, 38, 511-521.	2.7	3
554	Response to: â€˜Some concerns from Turkeyâ€™ by Bilginet al. Annals of the Rheumatic Diseases, 2020, 79, e16-e16.	0.9	3
555	Therapeutic perspectives on the metabolism of lymphocytes in patients with rheumatoid arthritis and systemic lupus erythematosus. Expert Review of Clinical Immunology, 2021, 17, 1121-1130.	3.0	3
556	Relationship between blood glucose variability in ambulatory glucose profile and standardized continuous glucose monitoring metrics: Subanalysis of a prospective cohort study. Diabetes, Obesity and Metabolism, 2022, 24, 82-93.	4.4	3
557	Pneumocystis carinii pneumonia in patients with connective tissue diseases. Japanese Journal of Clinical Immunology, 2002, 25, 310-318.	0.0	3
558	Successful treatment of osteomalacia caused by renal tubular acidosis associated with SjÃ¶grenâ€™s syndrome. Modern Rheumatology, 2013, 23, 401-405.	1.8	3

#	Article	IF	Citations
559	Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3). Modern Rheumatology, 2022, 32, 273-283.	1.8	3
560	Real-world effectiveness of liraglutide versus dulaglutide in Japanese patients with type 2 diabetes: a retrospective study. Scientific Reports, 2022, 12, 154.	3.3	3
561	Selection of treatment regimens based on shared decision-making in patients with rheumatoid arthritis on remission in the FREE-J study. Rheumatology, 2022, 61, 4273-4285.	1.9	3
562	The Efficacy and Safety of Anifrolumab in Japanese Patients With Systemic Lupus Erythematosus: TULIP-2 Subanalysis. Modern Rheumatology, 2022, , .	1.8	3
563	Soluble IL-6R promotes chondrogenic differentiation of mesenchymal stem cells to enhance the repair of articular cartilage defects using a rat model for rheumatoid arthritis. Clinical and Experimental Rheumatology, 2020, 38, 670-679.	0.8	3
564	Dawn of Precision Medicine in Psoriatic Arthritis. Frontiers in Medicine, 2022, 9, 851892.	2.6	3
565	Post hoc analysis of clinical characteristics of patients with radiographic progression in a Japanese phase 3 trial of peficitinib and methotrexate treatment (RAJ4). Modern Rheumatology, 2022, , .	1.8	3
566	Short-Term Prognostic Factors in Hospitalized Herpes Zoster Patients and Its Associated Cerebro-Cardiovascular Events: A Nationwide Retrospective Cohort in Japan. Frontiers in Medicine, 2022, 9, 843809.	2.6	3
567	Pericarditis induced by prophylactic administration of isoniazid in a patient with rheumatoid arthritis. Joint Bone Spine, 2011, 78, 99-100.	1.6	2
568	A case of catastrophic antiphospholipid antibody syndrome complicated with systemic lupus erythematosus, double positive for anti-cardiolipin/Î²2 glycoproteinÂI and anti-phosphatidylserine/prothrombin autoantibodies. Modern Rheumatology, 2012, 22, 769-773.	1.8	2
569	Systemic Lupus Erythematosus. Academic Radiology, 2014, 21, 617-623.	2.5	2
570	A multi-biomarker disease activity score for monitoring rheumatoid arthritis. Current Biomarker Findings, 2015, , 69.	0.4	2
571	Response to: â€˜Denosumab, cortical bone and bone erosion in rheumatoid arthritisâ€™ by Rossiniet al. Annals of the Rheumatic Diseases, 2016, 75, e71-e71.	0.9	2
572	Efficacy of Intravenous Cyclophosphamide Pulse Therapy for P-Glycoprotein-expressing B Cell-associated Active True Renal Lupus Vasculitis in Lupus Nephritis. Internal Medicine, 2017, 56, 1575-1580.	0.7	2
573	Comparison of the Effects of Teneligliptin and Sitagliptin, Two Dipeptidyl Peptidase 4 Inhibitors with Different Half-Lives, on Glucose Fluctuation and Glucagon-Like Peptide-1 in Type 2 Diabetes Mellitus. Journal of UOEH, 2018, 40, 1-9.	0.6	2
574	Design characteristics of the Corrona Japan rheumatoid arthritis registry. Modern Rheumatology, 2018, 28, 95-100.	1.8	2
575	Efficacy and Safety of Tofogliflozin on 24-h Glucose Profile Based on Continuous Glucose Monitoring: Crossover Study of Sodiumâ€“Glucose Cotransporter 2 Inhibitor. Diabetes Technology and Therapeutics, 2019, 21, 385-392.	4.4	2
576	Expression of the genes encoding hypothalamic feeding-related neuropeptides in the streptozotocin-induced diabetic rats with variable hyperglycemia and hyperphagia. Neuropeptides, 2019, 75, 34-40.	2.2	2

#	Article	IF	Citations
577	The two cases of acute acalculous cholecystitis associated with systemic lupus erythematosus (SLE) presented different clinical aspects. Modern Rheumatology Case Reports, 2019, 3, 114-118.	0.7	2
578	Predictive value of serum amyloid a levels for requirement of concomitant methotrexate in tocilizumab initiation: A post hoc analysis of the SURPRISE study. Modern Rheumatology, 2020, 30, 442-449.	1.8	2
579	P209â€ƒSafety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the select Phase 3 clinical programme. Rheumatology, 2020, 59, .	1.9	2
580	A case of bone destruction caused by chronic non-bacterial osteomyelitis (CNO) successfully repaired with a tumour necrosis factor-Î± (TNF-Î±) inhibitor, adalimumab. Modern Rheumatology Case Reports, 2020, 4, 196-201.	0.7	2
581	A case of eosinophilic granulomatosis with polyangiitis as a mimicker of IgG4-related disease. Modern Rheumatology Case Reports, 2020, 4, 278-282.	0.7	2
582	A phase 2a, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral gonadotropin-releasing hormone antagonist, ASP1707, in postmenopausal female patients with rheumatoid arthritis taking methotrexate. Modern Rheumatology, 2021, 31, 53-60.	1.8	2
583	<i>SOD2</i> mRNA as a potential biomarker for exercise: interventional and cross-sectional research in healthy subjects. Journal of Clinical Biochemistry and Nutrition, 2021, 69, 137-144.	1.4	2
584	Glucose-lowering effects of 7-day treatment with SGLT2 inhibitor confirmed by intermittently scanned continuous glucose monitoring in outpatients with type 1 diabetes. A pilot study. Endocrine Journal, 2021, 68, 361-369.	1.6	2
585	Work Environment-related Stress Factors are Correlated with Diabetes Development in Workers with Impaired Glucose Tolerance: A 5-year Follow-up Study Using the Brief Job Stress Questionnaire (BJSQ). Journal of UOEH, 2021, 43, 183-196.	0.6	2
586	The non-canonical Wnt5a/Ror2 signaling pathway in bone metabolism. Inflammation and Regeneration, 2014, 34, 103-108.	3.7	2
587	Correlations Between Glycemic Parameters Obtained from Continuous Glucose Monitoring and Hemoglobin A1c and Glycoalbumin Levels in Type 2 Diabetes Mellitus. Journal of UOEH, 2020, 42, 299-306.	0.6	2
588	A pooled analysis of serious infections and herpes zoster-related disease in Asian patients with rheumatoid arthritis treated with peficitinib (ASP015K) over a median of 3 years. Modern Rheumatology, 2022, 32, 708-717.	1.8	2
589	Immunogenicity of sarilumab and impact on safety and efficacy in Japanese patients with rheumatoid arthritis: analysis of two Phase 3 randomised clinical trials. Modern Rheumatology, 2022, 32, 686-695.	1.8	2
590	Structural damages disturb functional improvement in patients with rheumatoid arthritis treated with etanercept. Modern Rheumatology, 2012, 22, 186-194.	1.8	2
591	Prevention of joint destruction by tacrolimus in patients with early rheumatoid arthritis: a post hoc analysis of a double-blind, randomized, placebo-controlled study. Modern Rheumatology, 2013, 23, 1045-52.	1.8	2
592	Mild Encephalitis/Encephalopathy with Reversible Splenial Lesions in SLE. Internal Medicine, 2020, 59, 2439-2440.	0.7	2
593	Efficacy and safety of abatacept in biologic-naÃ¯ve patients with active rheumatoid arthritis by background methotrexate dose:post hocanalysis of a randomized, placebo-controlled, phase 4 study. Modern Rheumatology, 2022, 32, 500-507.	1.8	2
594	Long-term safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis: 3-year follow-up of a postmarketing surveillance. Modern Rheumatology, 2022, 32, 508-516.	1.8	2

#	Article	IF	Citations
595	Abatacept ameliorates both glandular and extraglandular involvements in patients with SjÃ¶grenâ€™s syndrome associated with rheumatoid arthritis: Findings from an open-label, multicentre, 1-year, prospective study: The ROSE (Rheumatoid Arthritis with Orencia Trial Toward SjÃ¶grenâ€™s Syndrome) Tj ETQq1 1 0.784314 rgBT /Ove	1.8	2
596	Integrated safety analysis of filgotinib treatment for rheumatoid arthritis in patients from Japan over a median of 1.5â€‰years. Modern Rheumatology, 2023, 33, 64-72.	1.8	2
597	Long-term safety and efficacy of belimumab in Japanese patients with SLE: A 7-year open-label continuation study. Modern Rheumatology, 2023, 33, 122-133.	1.8	2
598	Down-regulated Th17 cells in a patient with familial Mediterranean fever associated with amyloid A amyloidosis in the treatment of canakinumab. Modern Rheumatology Case Reports, 2022, , .	0.7	2
599	Efficacy of mizoribine treatment in patients with Sjï¿½gren?s syndrome: an open pilot trial. Modern Rheumatology, 2003, 13, 339-345.	1.8	2
600	Association Between Time in Range and Postprandial Glucose Contribution Rate in Non-Insulin-Treated Type 2 Diabetes Patients: Inverse Correlation of Time in Range with Postprandial Glucose Contribution Rate. Diabetes Technology and Therapeutics, 2022, 24, 805-813.	4.4	2
601	JAK inhibitor: tofacitinib, a new disease modifying anti-rheumatic drug. Inflammation and Regeneration, 2011, 31, 349-353.	3.7	1
602	The possible mode of action of Tofacitinib, a JAK inhibitor. Inflammation and Regeneration, 2014, 34, 129-133.	3.7	1
603	The occurrence of hypertrophic pachymeningitis with infiltration of IgG4-positive plasma cells and with different aetiology: report of three cases. Modern Rheumatology Case Reports, 2017, 1, 108-112.	0.7	1
604	Treatment with Methotrexate and Intravenous Cyclophosphamide Pulse Therapy Regulates the P-gp⁺CD4⁺ Cell-related Pathogenesis in a Representative Patient with Refractory Proliferative Lupus Nephritis. Internal Medicine, 2019, 58, 3173-3178.	0.7	1
605	Hypoglycemia in blood glucose level in type 2 diabetic Japanese patients by continuous glucose monitoring. Diabetology and Metabolic Syndrome, 2019, 11, 18.	2.7	1
606	THU0191â€…UPADACITINIB AS MONOTHERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS AT 48 WEEKS FROM THE SELECT-MONOTHERAPY STUDY. , 2019, , .		1
607	Scleroderma in an ice-cream shop worker. Rheumatology, 2019, 58, 1120-1121.	1.9	1
608	Focal Eosinophilic Myositis. Internal Medicine, 2020, 59, 141-141.	0.7	1
609	Effectiveness, safety, and methotrexate dose-tapering pattern over two years of treatment with adalimumab and â‰¥12â€‰mg/week methotrexate for early rheumatoid arthritis: Results of the HAWK postmarketing surveillance study in Japan. Modern Rheumatology, 2020, 30, 424-433.	1.8	1
610	A case of systemic lupus erythematosus in which Cushingâ€™s syndrome caused by adrenal adenoma accidentally occurred during long-term maintenance therapy with corticosteroids. Modern Rheumatology Case Reports, 2020, 4, 34-38.	0.7	1
611	An autopsy case of a patient with systemic sclerosis who developed marked pulmonary hypertension because of pulmonary tumor thrombotic microangiopathy caused by gastric carcinoma. Modern Rheumatology Case Reports, 2020, 4, 56-62.	0.7	1
612	P210â€ƒEfficacy and safety of filgotinib for patients with RA with inadequate response to methotrexate: FINCH1 primary outcome results. Rheumatology, 2020, 59, .	1.9	1

#	Article	IF	Citations
613	Systemic lupus erythematosus with repeated protein-losing enteropathy resulting from different pathological conditions: a case report. Modern Rheumatology Case Reports, 2020, 4, 229-232.	0.7	1
614	Short-term effectiveness of ixekizumab to refractory psoriatic arthritis with spondyloarthritis: two case reports. Modern Rheumatology Case Reports, 2020, 4, 176-180.	0.7	1
615	Fatal hemoperitoneum due to rupture of mesenteric artery in remission state of microscopic polyangiitis, concomitant with severe hypertension and posterior reversible encephalopathy syndrome: an autopsy case report. CEN Case Reports, 2021, 10, 549-558.	0.9	1
616	A Japanese Patient with Anti-PM/Scl and Centromere Antibody-Positive Scleroderma-Amyopathic Dermatomyositis Overlap Syndrome Who Developed Renal Crisis. Modern Rheumatology Case Reports, 2021, , .	0.7	1
617	Two patients with mixed connective tissue disease complicated by pulmonary arterial hypertension showing contrasting responses to pulmonary vasodilators. Modern Rheumatology Case Reports, 2020, 4, 253-261.	0.7	1
618	Intercellular adhesion molecule-1 (ICAM-1) mediated gene delivery to rheumatoid synovial cells using the Fab fragments of anti-ICAM-1 monoclonal antibody. Japanese Journal of Clinical Immunology, 2000, 23, 533-537.	0.0	1
619	Clinical implication of cyclosporin for systemic autoimmune diseases: relevance to multidrug resistance. Japanese Journal of Clinical Immunology, 2002, 25, 110-114.	0.0	1
620	Denosumab for the treatment of joint and bone diseases. Inflammation and Regeneration, 2011, 31, 344-348.	3.7	1
621	P-glycoprotein Expressing-B cell associated Active True Renal Lupus Vasculitis in Lupus Nephritis. , 2020, 5, .		1
622	Impact of age on the efficacy and safety of peficitinib (ASP015K) for the treatment of rheumatoid arthritis. Modern Rheumatology, 2022, 32, 696-707.	1.8	1
623	Subclinical synovitis detected by magnetic resonance imaging and ultrasonography following clinical remission in patients with rheumatoid arthritis: A retrospective study. Rheumatology & Autoimmunity, 2021, 1, 7-15.	0.8	1
624	Neuropsychiatric systemic lupus erythematosus detected using extravascular spillage signal on dynamic magnetic resonance imaging (Ktrans). Rheumatology, 2022, 61, SI102-SI104.	1.9	1
625	Mesenchymal stem cells: A new treatment tool for rheumatoid arthritis. Inflammation and Regeneration, 2012, 32, 188-192.	3.7	1
626	Regulatory role of mesenchymal stem cells in osteoclast differentiation. Inflammation and Regeneration, 2013, 33, 217-222.	3.7	1
627	Novel susceptibility loci for steroid-associated osteonecrosis of the femoral head in systemic lupus erythematosus. Human Molecular Genetics, 2022, 31, 1082-1095.	2.9	1
628	Clinical features of BehÃ§etâ€™s disease patients with joint symptoms in Japan: A national multicenter study. Modern Rheumatology, 2022, 32, 1146-1152.	1.8	1
629	A case of simultaneous onset of highly active systemic lupus erythematosus and IgG4-related renal disease. Modern Rheumatology Case Reports, 2022, 6, 178-182.	0.7	1
630	Prevention and management of herpes zoster in patients with rheumatoid arthritis and psoriatic arthritis: a clinical review. Clinical and Experimental Rheumatology, 2021, , .	0.8	1

#	Article	IF	Citations
631	A case of mixed connective tissue disease complicated by pulmonary hypertension and ascites after addition of pulmonary vasodilators. Modern Rheumatology Case Reports, 2022, , .	0.7	1
632	Allogeneic Stem Cell Transplantation for Trisomy 8-Positive Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Disease with Refractory BehÃ§etâ€™s Disease, Case Report and the Review of Literature. Modern Rheumatology Case Reports, 2022, , .	0.7	1
633	T helper cells expressing fractalkine receptor and bearing T follicular helper 1-like cell functions in patients with IgG4-related disease. Rheumatology, 2021, , .	1.9	1
634	Efficacy and safety of high-dose of mycophenolate mofetil compared with cyclophosphamide pulse therapy as induction therapy in Japanese patients with proliferative lupus nephritis. Modern Rheumatology, 2022, 32, 1077-1085.	1.8	1
635	OA29â€ƒClinical outcomes up to week 48 of filgotinib treatment in an ongoing long-term extension trial of RA patients with inadequate response to methotrexate initially treated with filgotinib or adalimumab during the Phase 3 Parent Trial. Rheumatology, 2022, 61, .	1.9	1
636	Additive combination of actarit and methotrexate in the treatment of refractory rheumatoid arthritis. Modern Rheumatology, 2000, 10, 103-109.	1.8	1
637	P220â€ƒLong-term safety profile of upadacitinib in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Rheumatology, 2022, 61, .	1.9	1
638	Severe skin ulceration associated with Wegenerâ€™s granulomatosis: successful treatment with hyperbaric oxygen and prostaglandin E₁. Modern Rheumatology, 2003, 13, 346-349.	1.8	0
639	Acro-Osteolysis and Symphalangism Mutations. Journal of Bone and Mineral Research, 2004, 20, 160-160.	2.8	0
640	Reply to Dr Pollono. Endocrine Journal, 2008, 55, 949.	1.6	0
641	EfficacitÃ© de lâ€™Ã©tanercept dans une cirrhose biliaire primitive associÃ©e Ã une polyarthrite rhumatoÃ¯de. Revue Du Rhumatisme (Edition Francaise), 2011, 78, 589-590.	0.0	0
642	Recent progress in small molecular products for the treatment of joint and bone diseases: an over view. Inflammation and Regeneration, 2011, 31, 341-343.	3.7	0
643	Signal transduction inhibitors for the treatment of rheumatoid arthritis. Arthritis Research and Therapy, 2012, 14, .	3.5	0
644	Abatacept inhibits radiographic progression in patients with rheumatoid arthritis: a retrospective analysis of 6Âmonths of abatacept treatment in routine clinical practice. The ALTAIR study. Modern Rheumatology, 2013, , 1.	1.8	0
645	Response to Dr Minota's Letter to the Editor of Modern Rheumatology Regarding a Study of Tofacitinib in Japanese Patients with Rheumatoid Arthritis. Modern Rheumatology, 2016, 26, 318-319.	1.8	0
646	Introducing the launch of Modern Rheumatology Case Reports. Modern Rheumatology Case Reports, 2017, 1, 1-1.	0.7	0
647	Glycemic Profiling in Patients with Drug-NaÃ¯ve Type 2 Diabetes by Continuous Glucose Monitoring. Journal of UOEH, 2018, 40, 287-297.	0.6	0
648	Risk Factors for Hypoglycemic Coma: A Study of 33 Patients on Insulin Therapy Who Were Transported to the Hospital by Ambulance. Internal Medicine, 2018, 57, 2923-2927.	0.7	0

#	Article	IF	Citations
649	Successful treatment with etanercept in a case of seronegative rheumatoid arthritis with corticosteroid/methotrexate-resistant pemphigus erythematosus. Modern Rheumatology Case Reports, 2018, 2, 137-142.	0.7	0
650	Small Molecules. , 2019, , 629-637.		0
651	Response to: â€˜Comment on â€˜Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trialâ€™ by Tanaka et alâ€™ by Berkhout et al. Annals of the Rheumatic Diseases, 2021, 80, e173-e173.	0.9	0
652	AB0416â€…A COMPARATIVE STUDY TO ASSESS THE EFFICACY, SAFETY, AND IMMUNOGENICITY OF YLB113 AND ETANERCEPT REFERENCE PRODUCT FOR THE TREATMENT OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS. , 2019, , .		0
653	SAT0126â€…A PHASE 2 STUDY OF E6011, AN ANTI-FRACTALKINE MONOCLONAL ANTIBODY, IN PATIENTS WITH RHEUMATOID ARTHRITIS INADEQUATELY RESPONDING TO BIOLOGICS. , 2019, , .		0
654	Response to: â€˜Tocilizumab in patients with adult-onset Stillâ€™s disease refractory to glucocorticoid treatmentâ€™ by Lee. Annals of the Rheumatic Diseases, 2019, 78, e134-e134.	0.9	0
655	Su1862 POOLED SAFETY ANALYSES FROM PHASE 3 STUDIES OF FILGOTINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS. Gastroenterology, 2020, 158, S-679.	1.3	0
656	O09â€ƒPooled safety analyses from Phase 3 studies of filgotinib in patients with RA. Rheumatology, 2020, 59, .	1.9	0
657	O8â€…Performance of the EULAR/ACR 2019 classification criteria for systemic lupus erythematosus in men, ethnicities, and early disease. , 2020, , .		0
658	Fulminant Type 1 Diabetes with Diversity in Peripheral Blood Lymphocytes: A Case Report. Journal of UOEH, 2020, 42, 57-62.	0.6	0
659	A refractory case of a male patient with neuropsychiatric systemic lupus erythematosus with various psychiatric symptoms and MRI observations. Clinical Neuropsychopharmacology and Therapeutics, 2020, 11, 1-4.	0.3	0
660	Case of autoimmune polyendocrine syndrome typeÂ3 complicated with antiâ€Nâ€methylâ€Dâ€aspartic acidâ€receptor encephalitis. Journal of Diabetes Investigation, 2021, 12, 290-292.	2.4	0
661	Lung transplantation resulted in marked improvement of autoimmunity and scleroderma in diffuse cutaneous systemic sclerosis: a case report. Rheumatology, 2021, 60, e129-e131.	1.9	0
662	Genome-oriented treatment strategies for autoimmune diseases. Inflammation and Regeneration, 2021, 41, 30.	3.7	0
663	Expression of the Chk2 Gene Is Downregulated in Hodgkinâ€™s Lymphoma Cell Lines Via Epigenetic Mechanisms.. Blood, 2004, 104, 429-429.	1.4	0
664	Effects of oxygen therapy during sleep in chronic dialysis patients with sleep-disordered breathing. Nihon Toseki Igakkai Zasshi, 2005, 38, 1187-1194.	0.1	0
665	Acetylation of an Ets Transcription Factor PU.1 Suppresses Its Transcriptional Activity.. Blood, 2007, 110, 2402-2402.	1.4	0
666	4. Drugs Targeting Intracellular Molecule: JAK Inhibitor and Syk Inhibitor. Japanese Journal of Clinical Pharmacology and Therapeutics, 2013, 44, 23-27.	0.1	0

#	Article	IF	Citations
667	Role of JAKs in myeloid cells and autoimmune diseases. Inflammation and Regeneration, 2013, 33, 131-135.	3.7	0
668	3ï¼ŽState-of-the-art Internal Medicine in Joints and Bone. The Journal of the Japanese Society of Internal Medicine, 2019, 108, 104a-111a.	0.0	0
669	Society of Internal Medicine, 2019, 108, 393-400.	0.0	0
670	3. State-of-the-art Internal Medicine in Joints and Bone. The Journal of the Japanese Society of Internal Medicine, 2019, 108, 1700-1712.	0.0	0
671	Predicting Disease Activity for Biologic Selection in Rheumatoid Arthritis. , 2020, , .		0
672	Hyperparathyroidism Which Developed after Resection of a Fibroblast Growth Factor 23-producing Tumor. Internal Medicine, 2020, 59, 2523-2527.	0.7	0
673	Association between ultrasound images and patient-reported outcomes in the treatment of rheumatoid arthritis: a retrospective study. BMC Rheumatology, 2021, 5, 49.	1.6	0
674	Discovery of a novel IgÎ² and FcÎ³RIIB cross-linking antibody, ASP2713, and its potential application in the treatment of systemic lupus erythematosus. International Immunopharmacology, 2021, 101, 108343.	3.8	0
675	Internal Medicine, 2020, 109, 1748-1758.	0.0	0
676	Efficacy of once-weekly teriparatide for primary prevention of glucocorticoid-induced osteoporosis: A post hoc analysis of the TOWER-GO study. Modern Rheumatology, 2021, , .	1.8	0
677	Corrigendum to: Digital pitting scars are associated with a severe disease course and death in systemic sclerosis: a study from the EUSTAR cohort. Rheumatology, 0, , .	1.9	0
678	Eplerenone Improves Vascular Endothelial Function in Patients with Primary Aldosteronism: A Pilot Study. Journal of UOEH, 2021, 43, 379-384.	0.6	0
679	Response of thyrotropin-secreting pituitary tumors to preoperative lanreotide therapy. Report of two cases. Neuroendocrinology Letters, 2020, 41, 10-16.	0.2	0
680	Difficult-to-treat rheumatoid arthritis with respect to responsiveness to biologic/targeted synthetic DMARDs: a retrospective cohort study from the FIRST registry. Clinical and Experimental Rheumatology, 2021, , .	0.8	0
681	Branched chain amino acids in the treatment of polymyositis and dermatomyositis: a phase II/III, multi-centre, randomized controlled trial. Rheumatology, 2022, , .	1.9	0
682	Rituximab in remission induction and maintenance therapy for microscopic polyangiitis associated with gastric cancer: A case report. Modern Rheumatology Case Reports, 2021, , .	0.7	0
683	P192â€ƒEfficacy of filgotinib in rheumatoid arthritis by age, body weight, body mass index: post hoc subgroup analysis of two phase 3 trials. Rheumatology, 2022, 61, .	1.9	0
684	Severe skin ulceration associated with Wegener?s granulomatosis: successful treatment with hyperbaric oxygen and prostaglandin E1. Modern Rheumatology, 2003, 13, 346-349.	1.8	0

#	Article	IF	Citations
685	Belimumab: A BAFF-specific Inhibitor for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis. , 2022, 1, 32.		0